Skip to main content

Ned Pagliarulo

Lead Editor |

Ned is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.

Email [email protected]

chevron

Submit a tip to our team

chevron

2243 articles by Ned Pagliarulo

Filter by month:

FDA approves cancer drugs from Lilly, Menarini
Jan. 30, 2023
FDA advisers back agency plan to simplify COVID-19 vaccination
Jan. 26, 2023
Bristol Myers says CAR-T therapy curbed leukemia in long-running study
Jan. 26, 2023
Merck reports one success, one setback from late-stage Keytruda trials
Jan. 25, 2023
Finch to lay off 95% of staff, scrap microbiome drug study
Jan. 24, 2023
FDA weighs shift in COVID vaccination strategy
Jan. 23, 2023
FDA rejects Lilly Alzheimer’s drug, citing insufficient data
Jan. 20, 2023
Editas, in next restructuring step, to sell cell therapy work to Shoreline
Jan. 19, 2023
Large study of J&J’s HIV vaccine stopped after shot found ineffective
Jan. 18, 2023
5 questions facing gene therapy in 2023
Jan. 12, 2023
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023
New Biogen CEO seeks to ‘redefine’ company after challenging year
Jan. 10, 2023
Editas to cut jobs, narrow research focus in restructuring
Jan. 9, 2023
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
Jan. 9, 2023
5 FDA decisions to watch in the first quarter
Jan. 9, 2023
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
Jan. 6, 2023
Bluebird bolsters balance sheet with sale of second regulatory fast pass
Jan. 6, 2023
FDA approves drugs from Gilead, Roche, TG Therapeutics to close 2022
Jan. 3, 2023
Disappearing IPOs, building startups and closing deals: Views from an up-and-down year in biotech
Jan. 3, 2023
Merck builds out cancer drug pipeline with Kelun-Biotech deal
Dec. 22, 2022
Doubts around cancer drug target persist after Gilead, Arcus study results offer ‘mixed picture’
Dec. 20, 2022
FDA lifts hold on Bluebird’s sickle cell gene therapy
Dec. 19, 2022
Third Harmonic halts study of lead drug over safety risk
Dec. 15, 2022
Kymera shares jump on Sanofi’s decision to advance protein-degrading drug
Dec. 14, 2022
Mirati’s KRAS-blocking cancer drug approved by FDA
Dec. 13, 2022
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
Dec. 12, 2022
Gene therapy approval won, Bluebird takes on next challenge: selling it
Dec. 12, 2022
Amgen to buy Horizon in year’s biggest biotech deal
Dec. 12, 2022
Esperion, without data, says cholesterol pill lowered heart risk in study
Dec. 7, 2022
Gene therapy approvals bring validation as field closes year on high
Dec. 6, 2022
Novartis prostate cancer drug succeeds in study key to company’s sales hopes
Dec. 5, 2022
SQZ CEO steps down as company restructures, cuts jobs
Dec. 1, 2022
Lilly’s Alzheimer’s drug bests Aduhelm in plaque clearance study
Dec. 1, 2022
Large pharmas probe takeover of Horizon Therapeutics
Nov. 30, 2022
What to make of Eisai and Biogen’s Alzheimer’s drug results
Nov. 29, 2022
State of Play: A closer look at hotspots of emerging biotech research
Nov. 29, 2022
FDA approves first gene therapy for hemophilia B
Nov. 22, 2022
GSK to pull blood cancer drug from US market after study failure
Nov. 22, 2022
Merck KGaA outlines plan to rev up drug R&D
Nov. 21, 2022
Editas to seek partner for CRISPR medicine after lackluster study results
Nov. 17, 2022
Biogen names former Sanofi head Viehbacher to replace Vounatsos as CEO
Nov. 10, 2022
Arrowhead capitalizes on Amgen drug progress with royalty rights deal
Nov. 9, 2022
BioMarin signals lengthier FDA review for hemophilia gene therapy
Nov. 8, 2022
GSK myeloma drug comes up short in confirmatory test
Nov. 7, 2022
Amgen to test new way to lower heart risk with large drug trial
Nov. 7, 2022
Bispecific cancer drugs and gene therapy advances: What to watch at this year’s ASH meeting
Nov. 4, 2022
RA Capital backs another startup hunting for a better antidepressant
Nov. 2, 2022
Lilly sales of new diabetes drug accelerate on rising patient demand
Nov. 1, 2022
Merck reveals chairman succession as earnings beat forecasts
Oct. 27, 2022
Novartis sales of Zolgensma gene therapy slow as market shifts
Oct. 25, 2022
Novartis rival to AstraZeneca rare disease drugs succeeds in study
Oct. 24, 2022
Pfizer planning steep price hike for COVID-19 vaccine
Oct. 21, 2022
Gilead, working to improve cancer cell therapy, partners with California startup
Oct. 20, 2022
AbbVie to buy UK biotech DJS for $255M
Oct. 20, 2022
FDA opens case to withdraw controversial drug for preterm births
Oct. 17, 2022
5 questions facing drugmakers as third quarter earnings begin
Oct. 17, 2022
‘We have to find a way’: FDA seeks solutions to aid bespoke gene therapy
Oct. 13, 2022
Odyssey recruits new investors to fund precision drug research
Oct. 13, 2022
Omicron boosters from Pfizer, Moderna cleared by FDA for younger children
Oct. 12, 2022
Vertex, after setbacks, moves forward with second-generation rare disease drug
Oct. 11, 2022
BIO’s McMurry-Heath steps down as head of biotech lobby
Oct. 11, 2022
Cytokinetics pushes on with late-stage study of ALS drug
Oct. 10, 2022
Biohaven starts life as new company following Pfizer buyout
Oct. 5, 2022
KalVista stops work on rare disease drug over safety concerns
Oct. 4, 2022
Former Spark CEO Marrazzo joins epigenetics startup’s board
Oct. 4, 2022
5 FDA decisions to watch in the fourth quarter
Oct. 3, 2022
Sanofi partners with Scribe to gain gene editing tools for cell therapy work
Sept. 27, 2022
Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’
Sept. 21, 2022
Merck to resume testing of closely watched HIV drug, but at lower dose
Sept. 20, 2022
Back-to-back gene therapy approvals give Bluebird shot at survival
Sept. 19, 2022
Bluebird wins FDA approval of gene therapy for rare brain disorder
Sept. 17, 2022
Alnylam, Regeneron to advance NASH drug after early signs of potential
Sept. 15, 2022
Amgen data supports KRAS cancer drug, but survival benefit remains in question
Sept. 12, 2022
How a top FDA official’s words helped push a closely watched ALS drug toward approval
Sept. 9, 2022
Relay impresses with early study data for targeted cancer drug
Sept. 8, 2022
Sarepta to restart Duchenne drug study after FDA lifts hold
Sept. 6, 2022
Sangamo presses ahead with Fabry disease gene therapy
Sept. 1, 2022
Amgen says KRAS drug beat chemo in lung cancer study
Aug. 31, 2022
‘Treg’ startup Sonoma expands with plans for manufacturing plant
Aug. 24, 2022
Pfizer, BioNTech submit omicron booster for FDA clearance
Aug. 22, 2022
Pharvaris studies of rare disease drug put on hold by FDA
Aug. 22, 2022
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Aug. 18, 2022
Bluebird gene therapy approved by FDA for rare blood disease
Aug. 17, 2022
Moderna, after firing newly hired CFO, finds replacement in PerkinElmer executive
Aug. 17, 2022
Novartis bid to repurpose rare disease drug for cancer falls short in third trial
Aug. 15, 2022
Amgen’s low tax rates draw attention of top Democratic senator
Aug. 12, 2022
Novartis reports deaths of two patients treated with Zolgensma gene therapy
Aug. 11, 2022
GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns
Aug. 11, 2022
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
Aug. 10, 2022
J&J’s head of R&D departs as pharma’s leadership turns over
Aug. 9, 2022
Samantha Truex on biotech hiring, competing for funding and Upstream’s next steps
Aug. 9, 2022
Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati
Aug. 8, 2022
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
Aug. 8, 2022
FDA approves AstraZeneca, Daiichi drug in breast cancer first
Aug. 5, 2022
Acadia turned back by FDA on second attempt to get psychosis drug approved
Aug. 5, 2022
Lilly takes long view on Alzheimer’s drug as FDA starts expedited review
Aug. 5, 2022
IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations
Aug. 2, 2022
Strand CEO on founder-led biotech, venture capital and the market’s retreat
Aug. 2, 2022
Concert to seek approval for hair loss drug after second study success
Aug. 1, 2022
AbbVie cancer drug sales fall as AstraZeneca competitor gains ground
July 29, 2022
Alnylam reveals longer wait for anticipated drug trial results
July 28, 2022
Editas treats first patient in sickle cell trial as FDA lifts partial hold
July 28, 2022
Bristol Myers CAR-T sales rise despite production problems
July 27, 2022
Versant partners with AbCellera to arm startups with better antibodies
July 27, 2022
BridgeBio advances drug for dwarfism after study data
July 26, 2022
Seagen, Astellas claim positive results in study key to cancer drug's success
July 26, 2022
China-based biotech licenses Sanofi's RNA drug technology
July 25, 2022
AstraZeneca, Daiichi breast cancer drug set for speedy FDA review
July 25, 2022
Astellas to bring research units under one roof in new West Coast center
July 22, 2022
Freeline gives detailed look at hemophilia gene therapy results
July 21, 2022
Novartis forecasts improving generic drug business as it weighs unit's future
July 19, 2022
Ultragenyx buys gene therapy partner after new study results
July 19, 2022
Drug deals, launches in focus as pharma earnings begin
July 18, 2022
Novo strikes $110M deal for regulatory fast pass
July 15, 2022
Novartis, BeiGene cancer drug faces delay as FDA puts off approval decision
July 14, 2022
Atara shares sink after update on multiple sclerosis trial
July 13, 2022
Verve starts first human test of gene editing treatment for heart disease
July 12, 2022
10 clinical trials to watch in the second half of 2022
July 5, 2022
5 FDA decisions to watch in the third quarter
June 29, 2022
J&J-backed gene therapy for the eye clears early study test
June 28, 2022
Relay details new research plans in quest to design better cancer drugs
June 27, 2022
Bristol Myers CAR-T therapy cleared by FDA for earlier lymphoma use
June 23, 2022
Novartis hunting for sickle cell cure with Precision deal
June 22, 2022
Mixed results for PTC Duchenne drug put spotlight on EU approval
June 21, 2022
FDA authorizes Pfizer, Moderna COVID-19 vaccines for young children
June 17, 2022
Pfizer study results show Paxlovid benefit less clear in lower-risk patients
June 15, 2022
Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost
June 14, 2022
FDA staff supportive of Pfizer, Moderna COVID vaccines in young children
June 13, 2022
FDA advisers offer unanimous support to second Bluebird gene therapy
June 10, 2022
FDA panel backs Bluebird gene therapy despite safety risks
June 9, 2022
Bluebird's future in balance as FDA weighs gene therapy approvals
June 9, 2022
ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy
June 6, 2022
FDA extends review of Amylyx ALS drug, delaying approval decision
June 3, 2022
Former AbbVie executive Severino joins Flagship-backed startup as CEO
June 2, 2022
Upstream Bio, a richly funded startup, reveals its lead drug and research plans
June 2, 2022
Sage, Biogen drug meets goal in postpartum depression study
June 1, 2022
BioMarin delays planned FDA filing for hemophilia gene therapy
May 31, 2022
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
May 26, 2022
3 cancer drug studies to watch at next month's ASCO meeting
May 26, 2022
Former Editas CEO Bosley joins UK venture capital firm
May 26, 2022
FDA starts clock on review of CSL, UniQure gene therapy
May 25, 2022
Springworks shares fall despite drug trial's success
May 24, 2022
Pfizer, Lilly bolster cases for experimental ulcerative colitis drugs
May 24, 2022
Concert drug helps regrow hair in study, boosting shares
May 23, 2022
Bayer backs out of Atara cell therapy deal
May 20, 2022
Ultragenyx strikes deal with struggling Abeona for rare disease gene therapy
May 17, 2022
Bristol Myers' Opdivo comes up short in bladder cancer trial
May 16, 2022
BridgeBio sale of FDA voucher good news for Bluebird, other biotech sellers
May 13, 2022
Bristol Myers acquires BridgeBio drug aimed at emerging cancer target
May 12, 2022
Former Novartis exec joins ADC Therapeutics as CEO after brief stint as Rafael head
May 9, 2022
J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic
May 9, 2022
Novartis suspends production of two radiopharmaceutical drugs over quality concerns
May 6, 2022
Intercept sells international rights to liver drug in $400M deal
May 5, 2022
Moderna vaccine sales surpass expectations as company looks to fall boosters
May 4, 2022
Vertex surprised by FDA halt of diabetes cell therapy study
May 2, 2022
Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug
April 22, 2022
Drug price hikes moderate as rebates rise, report finds
April 21, 2022
AbbVie ends research alliance on BioArctic Parkinson's drug
April 20, 2022
Satellite Bio launches with new approach to bioengineering tissues
April 20, 2022
Gilead gets cell therapy boost with FDA clearance of Maryland factory
April 19, 2022
GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history
April 13, 2022
Versant-backed startup launches with plans to broaden cell therapy's reach
April 13, 2022
AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T's reach
April 11, 2022
FDA advisers grapple with how to update COVID-19 vaccines
April 6, 2022
Novartis breast cancer drug approved for ultra-rare condition
April 6, 2022
Merck counting on heart drugs to boost business next decade
April 5, 2022
CAR-T treatment moves earlier as FDA widens approval of Gilead's Yescarta
April 4, 2022
Sanofi API spinout takes step toward market listing
April 1, 2022
5 FDA decisions to watch in the second quarter
March 31, 2022
Vertex gets positive trial results for non-opioid painkiller in boost to pipeline
March 31, 2022
Orchard turns to layoffs in cutting gene therapy research
March 30, 2022
FDA clears second COVID booster for older adults, immunocompromised
March 29, 2022
Pfizer inflammatory disease drug hits goal in second study
March 29, 2022
As biotech retreats, gene therapy companies retrench and redraw plans
March 24, 2022
Vertex plans path to FDA for top drug prospect
March 22, 2022
Bristol Myers melanoma drug approved by FDA in immunotherapy advance
March 21, 2022
Alnylam sues Pfizer, Moderna over technology used in COVID vaccines
March 17, 2022
FDA sets out advice to developers of gene editing medicines
March 16, 2022
Passage Bio to cut jobs in latest biotech restructuring
March 15, 2022
Nektar, Bristol Myers drug combination fails in late-stage melanoma trial
March 14, 2022
Novartis turns cell therapy skill into contract manufacturing deal
March 10, 2022
AbbVie holds off another Humira challenger with Alvotech deal
March 9, 2022
Novo sees fast growth ahead of obesity drugs despite production hurdles
March 4, 2022
Amid biotech downturn, Atlas raises $450M to build new drug startups
March 3, 2022
'We have to make a stand': Biotech leaders vow to break ties with Russia over Ukraine war
March 1, 2022
J&J, Legend cell therapy approved by FDA for multiple myeloma
Feb. 28, 2022
Moderna sued for allegedly infringing patents tied to COVID-19 vaccine
Feb. 28, 2022
Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down
Feb. 23, 2022
Adagio pledges to press forward with COVID drug as CEO to resign
Feb. 22, 2022
BioMarin says gene therapy hold will endure as FDA questions cancer risk
Feb. 18, 2022
Bristol Myers gets FDA decision date for earlier use of CAR-T therapy
Feb. 17, 2022
Third Harmonic, led by former Audentes CEO, launches with $155M in funding
Feb. 16, 2022
Amgen sees potential for KRAS drug in treating pancreatic cancer
Feb. 15, 2022
EMA follows FDA in scrutinizing safety of certain immune drugs
Feb. 14, 2022
ProQR eye drug comes up short in key study, surprising company and investors
Feb. 11, 2022
Pfizer aims to restart late-stage trial of Duchenne gene therapy following safety setback
Feb. 10, 2022
Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill
Feb. 8, 2022
Al Sandrock, former top Biogen scientist, to join drug discovery startup's board
Feb. 8, 2022
Pressed by Wall Street, pharma executives signal openness to M&A
Feb. 7, 2022
In England, Orchard secures rare agreement on gene therapy coverage
Feb. 4, 2022
Intellia, expanding in gene editing, buys startup Rewrite for $45M
Feb. 3, 2022
Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods
Feb. 1, 2022
Biogen buys into fast-advancing Roche cancer drug
Feb. 1, 2022
Pfizer stops development of once-promising heart drug, handing back rights to partner Ionis
Jan. 31, 2022
Biogen, facing pressure on all sides, sells stake in biosimilars business
Jan. 28, 2022
Atara sells cell therapy plant to Fujifilm for $100M
Jan. 27, 2022
Cortexyme to shift focus after FDA places hold on experimental Alzheimer's drug
Jan. 26, 2022
J&J 'constantly looking' at biotech M&A, but focused on small, mid-sized deals
Jan. 25, 2022
Gene editing startup Metagenomi raises $175M to advance research pipeline
Jan. 25, 2022
Merck drug for chronic cough rejected by FDA
Jan. 24, 2022
Roche sees cause for optimism with failed Huntington's disease drug. Others aren't so sure.
Jan. 21, 2022
Top Merck executive to depart company for CEO role at ingredients maker
Jan. 20, 2022
GSK loses R&D chief Barron to high-powered startup amid investor pressure
Jan. 19, 2022
Bluebird faces longer wait for FDA verdict on experimental gene therapies
Jan. 18, 2022
5 questions facing gene therapy in 2022
Jan. 13, 2022
JPM22: Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird's crucial year
Jan. 12, 2022
JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment
Jan. 11, 2022
Amgen partners with Arrakis to develop drugs aimed at RNA
Jan. 11, 2022
JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies
Jan. 10, 2022
BioMarin plans return to FDA with updated data on hemophilia gene therapy
Jan. 10, 2022
Pfizer expands into gene editing with Beam research deal
Jan. 10, 2022
AstraZeneca adds to rare disease drug pipeline with Neurimmune deal
Jan. 7, 2022
German Merck buys manufacturer of key component in mRNA medicines
Jan. 6, 2022
Novartis turns to Alnylam in research deal aimed at liver failure
Jan. 6, 2022
Pfizer, BioNTech bet mRNA can make a better shingles vaccine
Jan. 5, 2022
5 FDA approval decisions to watch in the first quarter
Jan. 5, 2022
Avrobio stops work on rare disease gene therapy after unexpected study results
Jan. 4, 2022
Sanofi to buy cancer immunotherapy biotech for $1B
Dec. 21, 2021
Bluebird hit with another hold for sickle cell gene therapy
Dec. 20, 2021
FDA OKs drugs from Amgen, Argenx, Intra-Cellular in year-end push
Dec. 20, 2021
Spark expands in Philadelphia, with new facility meant to be Roche's gene therapy hub
Dec. 17, 2021
EU regulator says member countries can use Pfizer's experimental COVID pill
Dec. 16, 2021
Flush with cash, large drugmakers turn to share buybacks, deals
Dec. 16, 2021
Sanofi, GSK say COVID vaccine works as booster, but delay key study results
Dec. 15, 2021
Two cancer cell therapy studies succeeded. Why did a third fail?
Dec. 14, 2021
CAR-T therapy trials show promise for earlier use in lymphoma
Dec. 12, 2021
Moderna reveals first study results for seasonal flu vaccine
Dec. 10, 2021
Lilly deepens research ties in China with biotech deal
Dec. 10, 2021
AstraZeneca antibody cleared by FDA for preventive use against COVID-19
Dec. 8, 2021
Omicron cuts Pfizer vaccine's potency, but data show booster may restore protection
Dec. 8, 2021
Acadia shares rise on study success for Rett syndrome drug
Dec. 7, 2021
A serial biotech entrepreneur launches his next startup with high-dollar backing
Dec. 7, 2021
Biohaven to seek FDA approval for second migraine drug after study success
Dec. 6, 2021
Former Immunomedics executive charged with insider trading around trial data
Dec. 3, 2021
Early tests suggest Vir, GSK antibody could hold up versus omicron
Dec. 2, 2021
Vertex, needing research spark, finds promising results in small study of kidney disease drug
Dec. 1, 2021
GSK hires away top Pfizer vaccine scientist
Nov. 30, 2021
Vaccine makers move quickly to confront omicron threat
Nov. 29, 2021
GSK dives into NASH, RNA interference with Arrowhead deal
Nov. 23, 2021
Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy
Nov. 22, 2021
Biogen seeking more information in investigation of Aduhelm patient's death
Nov. 19, 2021
FDA approves Merck's Keytruda as first immunotherapy for early kidney cancer
Nov. 18, 2021
European drugs regulator signals rejection likely for Biogen's Aduhelm
Nov. 17, 2021
Pfizer asks FDA to authorize COVID-19 pill
Nov. 16, 2021
Pfizer will allow generic drugmakers to produce promising COVID-19 pill
Nov. 16, 2021
Biden nominates Robert Califf to return as FDA head
Nov. 12, 2021
Cortexyme plans path forward for Alzheimer's drug that failed study
Nov. 12, 2021
J&J, world's largest drugmaker, plans to split in two
Nov. 12, 2021
Pfizer buys into Biohaven's fast-selling migraine medicine
Nov. 9, 2021
Mirati gives first look at KRAS drug combination in lung cancer
Nov. 8, 2021
Beam gets green light to begin first clinical test of base editing
Nov. 8, 2021
Moderna cuts vaccine sales, delivery targets for 2021
Nov. 4, 2021
Pfizer gene therapy research delayed by trial changes, safety questions
Nov. 3, 2021
Pfizer sales of COVID-19 vaccine climb, with tens of billions more expected next year
Nov. 2, 2021
Takeda reels in a cell therapy research partner with 'build-to-buy' deal
Oct. 27, 2021
FDA advisers support Pfizer's coronavirus vaccine for young children
Oct. 26, 2021
Cortexyme drug fails in Alzheimer's trial, but company sees validation of unorthodox approach
Oct. 26, 2021
Novartis to consider sale or separation of Sandoz business
Oct. 26, 2021
Novartis hits another setback in plan to repurpose rare disease drug in lung cancer
Oct. 25, 2021
What to watch at the FDA's high-stakes meeting on COVID-19 vaccines for kids
Oct. 22, 2021
Bluebird, winding down in Europe, withdraws another rare disease gene therapy
Oct. 21, 2021
J&J foresees end to not-for-profit sales of coronavirus vaccine
Oct. 19, 2021
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
Oct. 18, 2021
AstraZeneca immunotherapy combo extends survival in liver cancer trial
Oct. 15, 2021
Merck advantage grows as FDA approves Keytruda for first-line cervical cancer
Oct. 14, 2021
Relay’s targeted cancer drug could be safer than its competitors. Is it more effective?
Oct. 8, 2021
Intergalactic Therapeutics launches with $75M to build a new type of gene therapy
Oct. 7, 2021
Takeda halts studies of touted sleep disorder drug over safety concern
Oct. 6, 2021
J&J asks FDA to clear booster dose of its coronavirus vaccine
Oct. 5, 2021
Gilead wins approval of CAR-T therapy in adult leukemia
Oct. 4, 2021
5 FDA approval decisions to watch in the fourth quarter
Oct. 1, 2021
GSK, Merck KGaA end cancer drug partnership after study results disappoint
Oct. 1, 2021
After long wait, Editas reveals first data for CRISPR gene editing treatment
Sept. 29, 2021
Eisai, Biogen to test FDA by asking for approval of second Alzheimer's drug
Sept. 28, 2021
Biohaven's pipeline takes a hit as drug for rare neurological disease falls short in trial
Sept. 27, 2021
CDC recommends Pfizer booster shots for many, overruling advisers on broad use
Sept. 23, 2021
AstraZeneca strikes deal with university spinoff to turn RNA into drugs
Sept. 23, 2021
US buying 500M more doses of Pfizer coronavirus vaccine for donation to world
Sept. 22, 2021
Novartis pushes further into gene therapy for the eye with deal for Swiss startup
Sept. 21, 2021
ESMO21: Mirati sets new KRAS bar, AstraZeneca's breast cancer data and Keytruda challengers line up
Sept. 20, 2021
FDA advisers support booster dose of Pfizer vaccine in older or high-risk adults
Sept. 17, 2021
Lilly's COVID-19 antibody cleared by FDA for post-exposure prevention
Sept. 17, 2021
Amgen to advance KRAS drug combination after improved results in colon cancer
Sept. 16, 2021
US stocks up on COVID-19 antibody drugs amid shortage concerns
Sept. 15, 2021
Fourth trial volunteer dies in Astellas gene therapy study
Sept. 14, 2021
Departing FDA officials, WHO leaders argue against broad rollout of COVID-19 booster shots
Sept. 13, 2021
Apellis eye drug succeeds in one key study, but falls short in its twin
Sept. 9, 2021
'The sky is not falling.' Cautious optimism follows FDA meeting on gene therapy risks
Sept. 7, 2021
At FDA meeting, gene therapy experts wrestle with field's blindspots
Sept. 3, 2021
What to expect at the FDA's two-day meeting on gene therapy safety
Sept. 1, 2021
Hint of benefit in Alzheimer's drug study fuel stock surge for Swiss biotech
Aug. 31, 2021
Pfizer drug bests Sanofi, Regeneron's Dupixent in head-to-head study
Aug. 30, 2021
BioMarin wins European approval to sell drug for dwarfism
Aug. 27, 2021
Gilead wins reversal of $1.2B penalty in CAR-T patent case
Aug. 26, 2021
Pfizer taps McKinsey executive to lead dealmaking efforts
Aug. 26, 2021
Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium
Aug. 23, 2021
Cell, gene therapy company funding reaches new heights, despite setbacks
Aug. 19, 2021
US to offer coronavirus boosters to all Americans in aggressive plan to counter delta's spread
Aug. 18, 2021
Merck wins approval for cancer drug acquired in 2019 biotech buyout
Aug. 16, 2021
VA leaves Aduhelm off coverage list, recommending against controversial Alzheimer's drug
Aug. 12, 2021
SeaGen builds cancer drug pipeline with China biotech deal
Aug. 9, 2021
Startup EQRx to take drug price mission public through $1.8B SPAC deal
Aug. 6, 2021
Moderna says vaccine protective through six months, but warns boosters needed this fall
Aug. 5, 2021
HHS watchdog to review FDA accelerated approval process after Aduhelm controversy
Aug. 4, 2021
Sarepta adds another gene therapy to its ever-expanding pipeline
Aug. 4, 2021
Sanofi bets $3.2B on mRNA with deal to buy Translate Bio
Aug. 3, 2021
Caribou raises $304M in one of gene editing's most lucrative IPOs
July 23, 2021
Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'
July 22, 2021
J&J predicts faster coronavirus vaccine sales amid debate over boosters
July 21, 2021
Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion
July 20, 2021
Cytokinetics heart drug succeeds in mid-stage study, boosting shares
July 19, 2021
Questions on new Alzheimer's drug benefit, price loom large at ICER meeting
July 16, 2021
Galapagos shares sink as first data from touted drug program disappoints
July 15, 2021
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
July 12, 2021
Novo, in rare deal, buys rights to Prothena amyloidosis treatment
July 12, 2021
FDA, under fire for Alzheimer's drug approval, seeks investigation of review process
July 9, 2021
Biohaven beats expectations with fast sales of migraine drug
July 8, 2021
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
July 8, 2021
A well-funded cancer drug startup brings on GSK's Axel Hoos as CEO
July 7, 2021
Moderna puts seasonal flu vaccine ambitions to the test
July 7, 2021
Lilly, Boehringer say diabetes drug first to succeed in hard-to-treat heart failure
July 6, 2021
5 FDA decisions to watch in the third quarter
July 2, 2021
CureVac vows to seek vaccine approval despite low efficacy in COVID-19 study
July 1, 2021
Beam, Apellis partner in deal to expand gene editing's reach
June 30, 2021
ICER stands by view on Biogen's Aduhelm, says sharp price cut needed
June 30, 2021
Gilead, Foresite back biotech developer of COVID-19 pill in latest SPAC deal
June 29, 2021
Gilead matches Bristol Myers in showing benefit to earlier CAR-T treatment
June 28, 2021
FDA advisers vote down Incyte cancer drug as agency takes tougher line
June 25, 2021
Reversing course, Lilly to seek fast approval for experimental Alzheimer's drug
June 24, 2021
Third Rock-backed startup launches to develop cell therapies for MS, diabetes
June 23, 2021
FDA documents show how controversial Alzheimer's drug decision was reached
June 22, 2021
Blackstone to invest $250M in cell therapy startup backed by Intellia, Cellex
June 22, 2021
GSK, Vir build case for COVID-19 antibody drug with new study data
June 21, 2021
US to invest $3B in research quest for COVID-19 pill
June 18, 2021
Gene editing biotech Verve to raise $267M in large IPO
June 17, 2021
Sage antidepressant succeeds in key study, but data raise questions
June 15, 2021
Novavax says vaccine 90% effective against COVID-19 in large trial
June 14, 2021
Blood disease treatment from CRISPR, Vertex shows promise in more patients
June 11, 2021
Bristol Myers says CAR-T therapy beat chemo, transplant in lymphoma study
June 10, 2021
Beigene expands into cancer cell therapy with Shoreline pact
June 9, 2021
The FDA approved Biogen's Alzheimer's drug. The company now has years to confirm it works.
June 8, 2021
Bluebird cleared by FDA to resume studies of sickle cell gene therapy
June 7, 2021
ASCO21: An immunotherapy debate, an NK cell question and the next precision drugs
June 7, 2021
Bristol Myers sued over delayed approval of cancer cell therapy
June 4, 2021
Novartis prostate cancer drug extends survival in key test of radiopharmaceutical therapy
June 3, 2021
Bayer buys a biotech and its offshoot in bet on radiopharmaceuticals
June 3, 2021
MorphoSys to buy Constellation in $1.7B deal, aided by unusual funding
June 2, 2021
Sanofi rare disease drug hits another setback
June 1, 2021
In first, FDA approves KRAS-blocking cancer drug from Amgen
May 28, 2021
Centessa raises $330M in third largest biotech IPO this year
May 28, 2021
'A hugely consequential decision:' How Biogen's Alzheimer's drug came to face the FDA
May 27, 2021
Off-the-shelf CAR-T, a Tagrisso rival and the next breast cancer drugs
May 20, 2021
Closely watched Bristol Myers immunotherapy shows benefit in melanoma
May 19, 2021
FDA seeking more consistency from cell, gene therapy developers, top official says
May 19, 2021
Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target
May 18, 2021
Novartis challenge to Amgen's Enbrel patents ends at Supreme Court's door
May 18, 2021
Sanofi, GSK say revamped coronavirus vaccine is strong enough for final test
May 17, 2021
Biogen gene therapy misses goal in eye disease study
May 14, 2021
CDC panel endorses Pfizer vaccine for 12- to 15-year-olds
May 12, 2021
Ginkgo Bioworks to go public through $2.5B SPAC deal
May 11, 2021
FDA authorizes Pfizer's coronavirus vaccine for younger teens
May 10, 2021
Amgen asks FDA for approval of key asthma drug
May 10, 2021
Pharma erupts as Biden administration backs waiver of vaccine patent rights
May 6, 2021
ICER, unconvinced by Biogen data, suggests low price for Alzheimer's drug
May 5, 2021
Pfizer forecasts $26B in coronavirus vaccine revenue this year
May 4, 2021
Avrobio changes course after FDA closes path for speedy gene therapy approval
May 3, 2021
FDA faces tough choice after panel backs speedy cancer drug approvals
April 30, 2021
Emergent CEO defends company from criticism of error that ruined vaccine doses
April 30, 2021
Merck, GSK vaccine sales hit by pandemic as competitors' business booms
April 29, 2021
BioMarin partners with Allen Institute to develop gene therapies for the brain
April 28, 2021
Gilead, Merck to help India access COVID-19 drugs as country's crisis deepens
April 27, 2021
Sanofi to aid Moderna on final steps in manufacturing coronavirus vaccine
April 26, 2021
FDA, CDC support resuming use of J&J vaccine after advisory panel vote
April 23, 2021
GSK immunotherapy wins FDA approval, joining crowded cancer drug class
April 23, 2021
A look ahead at the FDA meeting that could decide the future of 6 cancer drug approvals
April 22, 2021
FDA cites Emergent for failings at plant that contaminated J&J doses
April 22, 2021
The next 2 months in biotech and pharma will be busy. Here's what to watch.
April 20, 2021
Bluebird to withdraw gene therapy from Germany after dispute over price
April 20, 2021
Relay buys AI startup to aid unorthodox drug discovery quest
April 16, 2021
GSK stops studies testing closely watched cancer immunotherapy
April 15, 2021
The US paused use of J&J's vaccine. What happens next?
April 13, 2021
US recommends pause in J&J vaccinations due to concerns over rare blood clots
April 13, 2021
Lilly, Arch join Deerfield in backing new gene therapy biotech Jaguar
April 13, 2021
5 takeaways from AACR, one of the year's top meetings on cancer drugs
April 12, 2021
Lilly gene-targeted drug shows potential for use across cancers
April 11, 2021
Researchers lay out hypothesis for rare side effect linked to AstraZeneca vaccine
April 9, 2021
Lilly claims promising finding in failed study of COVID-19 drug
April 8, 2021
Bluebird executive joins Flagship startup Tessera as CMO
April 7, 2021
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
April 6, 2021
J&J to oversee vaccine production at Emergent factory that ruined doses
April 5, 2021
Manufacturing mix-up could blunt supply boost from J&J vaccine
April 1, 2021
Audentes CEO exits as Astellas rebrands a gene therapy buyout
April 1, 2021
Akebia tries for FDA approval of anemia drug after mixed data
March 30, 2021
UniQure says hemophilia gene therapy likely not cause of study volunteer's cancer
March 29, 2021
FDA approves first CAR-T cell therapy for multiple myeloma
March 27, 2021
Slaoui steps down from two more biotechs after harassment claim
March 25, 2021
Moncef Slaoui, who led US Warp Speed effort, accused of sexual harassment
March 24, 2021
FDA won't review Novo diabetes drug in latest case of regulatory pushback
March 23, 2021
AstraZeneca may have used 'outdated' data to describe vaccine's efficacy, NIH says
March 23, 2021
Bluebird's top doctor to depart as company grapples with safety review
March 17, 2021
Record funding flowed into cell, gene therapy companies last year
March 16, 2021
Elevate Bio raises half a billion dollars to fuel cell, gene therapy expansion
March 15, 2021
Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots
March 11, 2021
Bluebird says gene therapy 'very unlikely' cause of cancer case in trial
March 10, 2021
Biotech's deal refusals led to pricey buyout by Merck
March 5, 2021
Amgen, with rare buyout, pays $1.9B for cancer biotech Five Prime
March 4, 2021
FibroGen shares sink as FDA meeting decision suggests another delay for top drug
March 2, 2021
J&J's 1-dose coronavirus vaccine becomes third available in US
Feb. 27, 2021
FDA panel backs J&J's coronavirus vaccine, clearing way for shot's authorization
Feb. 26, 2021
Bluebird reveals new details on cancer cases in gene therapy trial
Feb. 26, 2021
A play-by-play of the FDA meeting on J&J's vaccine
Feb. 26, 2021
Top Moderna executive to leave company later this year
Feb. 25, 2021
Former AveXis executives launch gene therapy startup with uncommon targets
Feb. 25, 2021
FDA review supports safety, efficacy of J&J coronavirus vaccine
Feb. 24, 2021
Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M
Feb. 23, 2021
FDA lays out shortened path for testing vaccines against new coronavirus variants
Feb. 22, 2021
Why this week's FDA meeting on J&J's coronavirus vaccine will be important
Feb. 22, 2021
Pfizer set to double weekly production of coronavirus vaccine
Feb. 19, 2021
Bluebird stops studies of sickle cell gene therapy after new cancer cases
Feb. 16, 2021
10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model
Feb. 16, 2021
A gene therapy pipeline takes shape for a cluster of rare diseases
Feb. 12, 2021
US secures 200 million more vaccine doses from Pfizer, Moderna
Feb. 12, 2021
FDA clears Lilly's COVID-19 antibody cocktail for emergency use
Feb. 10, 2021
Editas names new CEO in latest executive shakeup
Feb. 8, 2021
Bristol Myers finally wins FDA approval for cancer cell therapy
Feb. 5, 2021
Gilead sales propped up by COVID-19 drug Veklury
Feb. 5, 2021
J&J asks FDA for emergency clearance of coronavirus vaccine
Feb. 4, 2021
Ken Frazier, veteran pharma leader, to step down as Merck CEO
Feb. 4, 2021
Jazz Pharma to buy GW Pharma, maker of CBD-based epilepsy drug, for $7.2B
Feb. 3, 2021
Pfizer forecasts $15B sales boost from coronavirus vaccine orders
Feb. 2, 2021
Bayer agrees to help CureVac produce coronavirus vaccine
Feb. 1, 2021
Gilead partners with a cancer biotech, seeking to develop an HIV immunotherapy
Feb. 1, 2021
J&J says single dose of coronavirus vaccine 66% effective in large trial
Jan. 29, 2021
Amgen study data bolster prospects of KRAS-blocking cancer drug
Jan. 28, 2021
Lilly strikes deal to acquire drug for chronic pain
Jan. 28, 2021
Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses
Jan. 26, 2021
J&J says study data on coronavirus vaccine due 'early next week'
Jan. 26, 2021
Moderna to study vaccine booster aimed at coronavirus variant
Jan. 25, 2021
Pricing challenge looms for Novartis as cholesterol drug's US fate remains unclear
Jan. 22, 2021
Lilly's antibody drug prevents COVID-19 in study, but hurdles to use remain
Jan. 20, 2021
Beam, Verve stockpile cash as investors bank on gene editing progress
Jan. 19, 2021
JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's research and Pfizer's deep pockets
Jan. 12, 2021
Bluebird to split company, spin off cancer drug business
Jan. 11, 2021
BioMarin tries to get hemophilia gene therapy back on track with positive data
Jan. 11, 2021
5 questions facing gene therapy in 2021
Jan. 8, 2021
5 FDA approval decisions to watch in the 1st quarter
Jan. 5, 2021
How an all-or-nothing bet on 3 Bristol Myers drugs came undone
Jan. 4, 2021
Pfizer, BioNTech win EU vaccine approval as UK grapples with new coronavirus variant
Dec. 22, 2020
FDA delays decision on Novartis cholesterol therapy
Dec. 21, 2020
Changing identity, Agios to sell cancer drug business to Servier
Dec. 21, 2020
FDA panel endorses Moderna's coronavirus vaccine
Dec. 17, 2020
A play-by-play of the FDA meeting on Moderna's coronavirus vaccine
Dec. 17, 2020
FDA scientists back safety, efficacy of Moderna's coronavirus vaccine
Dec. 15, 2020
Relay Therapeutics, fresh off IPO, partners with Roche in cancer drug deal
Dec. 14, 2020
Viatris to lay off staff, shutter plants in major restructuring
Dec. 11, 2020
FDA advisers back Pfizer, BioNTech vaccine, clearing way for emergency approval
Dec. 10, 2020
A play-by-play of the historic FDA meeting on Pfizer and BioNTech's coronavirus vaccine
Dec. 9, 2020
Vaccine Developers of the Year: BioNTech and Moderna
Dec. 9, 2020
FDA scientists appear supportive of Pfizer, BioNTech's coronavirus vaccine
Dec. 8, 2020
Lilly to pit Loxo cancer drug against top-selling rival after strong study results
Dec. 7, 2020
Vaccine production in focus as Moderna, Pfizer await FDA decision
Dec. 4, 2020
4 storylines to track at the year's biggest meeting on blood diseases
Dec. 3, 2020
Merck, expanding coronavirus work, buys a small biotech and its COVID-19 drug
Nov. 23, 2020
Trump administration pushes last-ditch plans to lower drug prices
Nov. 20, 2020
Pfizer, BioNTech ask FDA for emergency approval of coronavirus vaccine
Nov. 20, 2020
UniQure's gene therapy for hemophilia B meets goal in key study
Nov. 19, 2020
New coronavirus vaccine data bolster Pfizer, BioNTech claims of strongly effective shot
Nov. 18, 2020
Trial success for 2 coronavirus vaccines backs up early research bets
Nov. 17, 2020
Moderna close to having results from key coronavirus vaccine trial
Nov. 12, 2020
Pfizer and BioNTech's coronavirus vaccine works. Here's what we still don't know.
Nov. 10, 2020
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
Nov. 9, 2020
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Nov. 6, 2020
BioMarin, stung by FDA rejection, pressed on path forward for 2 key drugs
Nov. 6, 2020
Biogen surges as FDA reviewers appear supportive of Alzheimer's drug approval
Nov. 4, 2020
Bristol Myers bet pays off as psoriasis drug beats Amgen rival in study
Nov. 3, 2020
AstraZeneca partners with Fusion to test radiopharmaceuticals in cancer
Nov. 2, 2020
Axovant shares sink on manufacturing delay for Parkinson's gene therapy
Oct. 30, 2020
Gilead lifted by fast sales of COVID-19 drug Veklury. Will they last?
Oct. 29, 2020
US to pay Lilly $375M for supply of COVID-19 drug
Oct. 28, 2020
5 takeaways from the FDA's closely watched coronavirus vaccine meeting
Oct. 24, 2020
AstraZeneca, J&J cleared to restart major coronavirus vaccine studies
Oct. 23, 2020
Ultragenyx expands into Duchenne gene therapy with Solid Bio deal
Oct. 23, 2020
At key meeting, FDA advisors debate if early coronavirus vaccine approvals may compromise trials
Oct. 23, 2020
Moderna enrolls final volunteers into key coronavirus vaccine study
Oct. 22, 2020
Merck, with more study data, builds case for pneumonia vaccine successor
Oct. 20, 2020
Intellia cleared to start key CRISPR drug study in UK
Oct. 19, 2020
Gilead's COVID-19 drug doesn't prevent deaths, large WHO study finds
Oct. 16, 2020
Fujifilm to help Lilly make COVID-19 antibody drug
Oct. 15, 2020
FDA approves Regeneron antibody drug as first Ebola virus treatment
Oct. 14, 2020
NIH study of Lilly COVID-19 antibody drug paused for safety review
Oct. 13, 2020
J&J halts studies of coronavirus vaccine due to participant's illness
Oct. 13, 2020
Mallinckrodt, beset by opioid drug suits, files for bankruptcy
Oct. 12, 2020
US backs AstraZeneca COVID-19 antibody drug with $486M in funding
Oct. 9, 2020
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
Oct. 9, 2020
Amgen and Cytokinetics claim heart drug success, but results widely disappoint
Oct. 8, 2020
FDA releases coronavirus vaccine guidelines that White House resisted
Oct. 6, 2020
FDA told coronavirus vaccine makers of stricter standards for early approval
Oct. 6, 2020
Trump treated for COVID-19 with Regeneron, Gilead drugs
Oct. 2, 2020
Merck research chief Roger Perlmutter to retire, leaving immunotherapy legacy
Oct. 2, 2020
Gilead to distribute COVID-19 drug Veklury in US, taking over from federal government
Oct. 2, 2020
Private equity-backed Covis to buy AMAG Pharma in $650M deal
Oct. 1, 2020
Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge
Oct. 1, 2020
5 FDA approval decisions to watch in the 4th quarter
Sept. 29, 2020
J&J, beginning final test, shares first data on coronavirus vaccine
Sept. 25, 2020
Drugmakers push forward on large-scale production of coronavirus vaccines
Sept. 24, 2020
Trump undercuts FDA on coronavirus vaccine authorization plans
Sept. 24, 2020
J&J begins largest Phase 3 study of a coronavirus vaccine
Sept. 23, 2020
Blueprint's bet on itself pays off with rare disease drug data
Sept. 22, 2020
Merck matches Roche in search for next cancer immunotherapy
Sept. 21, 2020
Amgen's KRAS drug can shrink tumors for months, but new data leave room for improvement
Sept. 20, 2020
Moderna and Pfizer, having shown speed with coronavirus vaccines, see opportunity in seasonal flu
Sept. 17, 2020
Vaccine makers, in bid for transparency, disclose detailed plans of coronavirus vaccine trials
Sept. 17, 2020
Pfizer says coronavirus vaccine study still on track for October readout
Sept. 15, 2020
Takeda adds to cell therapy push with new manufacturing site
Sept. 15, 2020
Lilly says its arthritis drug helps speed COVID-19 recovery
Sept. 14, 2020
Gilead to buy cancer drugmaker Immunomedics for $21B
Sept. 13, 2020
How biotech and pharma companies pay their CEOs, and their workers
Sept. 9, 2020
Studies of AstraZeneca coronavirus vaccine put on hold for safety review
Sept. 8, 2020
Amarin loses appeal of court ruling on heart drug patents
Sept. 3, 2020
Intercept, facing long road ahead for NASH drug, lays off quarter of workforce
Sept. 2, 2020
NIH panel says data doesn't support plasma use for COVID-19
Sept. 2, 2020
Relay Therapeutics set out to change how drugs are designed. Can it continue what Vertex began?
Aug. 24, 2020
In major surprise, FDA rejects high-profile therapies from BioMarin, Gilead
Aug. 19, 2020
Sanofi, seeking control of key drug, to buy Principia for $3.7B
Aug. 17, 2020
Europe, trailing US, UK, reaches first coronavirus vaccine deal
Aug. 14, 2020
CanSino rides coronavirus vaccine progress to lucrative Shanghai market debut
Aug. 13, 2020
Moderna gets $1.5B from US for coronavirus vaccine supply
Aug. 11, 2020
Russia, with scant study data, approves coronavirus vaccine
Aug. 11, 2020
US puts Kodak loan on hold after stock scrutiny
Aug. 10, 2020
Pfizer to help Gilead produce COVID-19 drug remdesivir
Aug. 7, 2020
GSK wins US approval for first-of-its-kind blood cancer drug
Aug. 6, 2020
Moderna sets high price in early coronavirus vaccine supply deals
Aug. 5, 2020
Novartis says CAR-T cancer therapy works in second lymphoma type
Aug. 4, 2020
Bausch Health to pay $45M to settle US charges over Valeant-era accounting
Aug. 3, 2020
Merck nears clinical tests for coronavirus vaccine candidates
July 31, 2020
US promises $2.1B to Sanofi, GSK in latest coronavirus vaccine deal
July 31, 2020
Pfizer spinoff Cerevel to raise $445M in merger with blank-check company
July 30, 2020
US taps camera makers for help manufacturing drugs, vaccines
July 28, 2020
AstraZeneca turns again to Daiichi Sankyo for a major cancer drug deal
July 27, 2020
Early coronavirus vaccine data leave many questions, but some lessons, too
July 23, 2020
US to pay nearly $2B for supply of Pfizer, BioNTech coronavirus vaccine
July 22, 2020
Biogen to study use of key SMA drug after Novartis gene therapy
July 21, 2020
CanSino coronavirus vaccine clears mid-stage test, but data show its limits
July 20, 2020
J&J, on the cusp of starting coronavirus vaccine trials, sets high bar for success
July 16, 2020
Researchers publish long-awaited study data on Moderna coronavirus vaccine
July 14, 2020
Sanofi turns to MD Anderson to help fuel cancer drug push
July 14, 2020
Beigene, already flush with cash, raising $2B from investors
July 13, 2020
In the UK, a coronavirus study shows how to get fast, powerful data during a pandemic
July 10, 2020
5 FDA approval decisions to watch in the 3rd quarter
July 8, 2020
Novavax gets $1.6B in US funding for coronavirus vaccine
July 7, 2020
J&J, with new deal, plans for long-term manufacture of coronavirus vaccine
July 6, 2020
Novartis to pay $678M to settle claims over 'sham' doctor events
July 2, 2020
Coronavirus vaccine from Pfizer, BioNTech shows early potential
July 1, 2020
FDA insists it 'will not cut corners' in coronavirus vaccine approvals
June 30, 2020
Large UK study finds no benefit to HIV antiviral in COVID-19
June 30, 2020
Gilead sets price for COVID-19 drug remdesivir
June 29, 2020
WHO lays out ambitious plan to deliver 2 billion coronavirus vaccine doses
June 26, 2020
Trailing leaders, Sanofi speeds coronavirus vaccine plans
June 23, 2020
Gilead to launch studies of inhaled version of COVID-19 drug remdesivir
June 22, 2020
Merck gives 1st look at Phase 3 results for its Prevnar competitor
June 22, 2020
Chinese biotech to test GSK, Dynavax adjuvants in coronavirus vaccine study
June 19, 2020
With new proposal, Trump administration tries to encourage 'value-based' drug deals
June 18, 2020
'Warp Speed' plan for coronavirus vaccines comes into focus
June 17, 2020
FDA revokes emergency clearance for hydroxychloroquine, citing new data, risks
June 15, 2020
Sinovac claims progress with early coronavirus vaccine study
June 15, 2020
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
June 12, 2020
US invests in drug vials to support coronavirus vaccine push
June 9, 2020
Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands.
June 9, 2020
Lilly gets a 2nd COVID-19 antibody into clinical trials with Junshi's help
June 8, 2020
Case for hydroxychloroquine in COVID-19 fades as key UK study finds no benefit
June 5, 2020
'Warp Speed' push for coronavirus vaccine accelerates as White House reportedly narrows field
June 4, 2020
Hydroxychloroquine offers no COVID-19 protection after exposure, study shows
June 3, 2020
US government promises Maryland drug manufacturer $628M to make coronavirus vaccines
June 2, 2020
COVID-19 could slow progress in reducing cancer death, NCI head warns
June 1, 2020
Facing vial shortage, pharmas explore workarounds for coronavirus vaccines
May 28, 2020
Coronavirus vaccine developers plan to enroll tens of thousands in late-stage tests
May 28, 2020
Merck makes COVID-19 drug plans clear with flurry of deals
May 26, 2020
New study details show remdesivir speeds COVID-19 recovery, but doesn't help sickest patients
May 23, 2020
Coronavirus study in China shows CanSino's vaccine spurs immune responses
May 22, 2020
Biotech companies raise cash as coronavirus updates lift stocks
May 19, 2020
'Operation Warp Speed,' unveiled by Trump, aims for coronavirus vaccine by year's end
May 15, 2020
Cancer biotech stocks shift on glimpse of ASCO data
May 14, 2020
Roche unveils first data for new type of cancer immunotherapy
May 13, 2020
Surprise setback for Bristol, Bluebird as FDA rejects cell therapy application
May 13, 2020
Trump administration: States to decide which hospitals get Gilead's COVID-19 drug
May 11, 2020
Lilly's Loxo buyout bears fruit as FDA clears cancer drug Retevmo
May 9, 2020
Moderna plans earlier start to late-stage test of coronavirus vaccine
May 7, 2020
Ousted BARDA director claims retaliation for pushing back on unproven coronavirus drugs
May 5, 2020
Alexion, seeking to broaden business, to buy Portola for $1.4B
May 5, 2020
With new estimate, ICER sets terms of debate on pricing Gilead's COVID-19 drug
May 4, 2020
Gilead's remdesivir, shown to hasten COVID-19 recovery, cleared for emergency use by FDA
May 1, 2020
Gilead may have a drug for COVID-19. Wall Street asks whether it will profit
May 1, 2020
'We really did need a win.' Gilead drug no knockout in COVID-19, but results spur optimism
April 30, 2020
Gilead drug for COVID-19 clears crucial clinical test
April 29, 2020
Pharmas boosted by drug stockpiling, but warn of COVID-19 impact
April 28, 2020
Regeneron, Sanofi immunotherapy extends survival in previously untreated lung cancer
April 27, 2020
Sanofi CEO cautions arthritis drug a 'long shot' in COVID-19, says study results 'imminent'
April 24, 2020
Leaked data on Gilead's remdesivir suggest drug didn't help patients with COVID-19
April 23, 2020
Immunomedics wins long-sought FDA approval for breast cancer drug
April 22, 2020
Coronavirus vaccine from BioNTech, Pfizer set to enter testing in Germany
April 22, 2020
BARDA director says he was ousted for 'clashes' with HHS over unproven therapies
April 21, 2020
Novartis, launching COVID-19 trial, seeks to prove hydroxychloroquine's worth
April 20, 2020
US government to back Moderna's coronavirus vaccine with up to $483M
April 16, 2020
As Ebola drug review starts, Regeneron hopes to chart similar path for coronavirus therapy
April 16, 2020
AstraZeneca to study leukemia drug as COVID-19 treatment
April 15, 2020
In rare move, Sanofi and GSK ally on coronavirus vaccine development
April 14, 2020
Early data on Gilead coronavirus drug raises hope, but answers few questions
April 11, 2020
Pfizer accelerates clinical trial plans for coronavirus drug
April 9, 2020
Sage to lay off half of workforce in cost-cutting retrenchment
April 7, 2020
Inovio begins first human test of experimental coronavirus vaccine
April 7, 2020
Gilead working to quickly boost production of experimental coronavirus drug
April 6, 2020
Incyte, Novartis to test repurposed cancer drug in COVID-19
April 3, 2020
Amgen, partnering with Seattle's Adaptive, begins coronavirus drug search
April 2, 2020
Amarin shares slump as surprising court defeat puts Vascepa at risk
March 31, 2020
No sanctions for Novartis as FDA ends review of gene therapy violations
March 30, 2020
FDA clears emergency use of malaria pills to treat COVID-19
March 30, 2020
For CAR-T, coronavirus brings uneven impact to studies, treatment
March 27, 2020
AstraZeneca turns again to UK's Silence in renewed RNAi push
March 25, 2020
Coronavirus forces ASCO, cancer research's top meeting, to move online
March 24, 2020
Gilead, flooded with requests, suspends access to experimental coronavirus drug
March 23, 2020
Drugmakers boost production of malaria pill touted by Trump as coronavirus treatment
March 20, 2020
Despite 'heroic' effort, coronavirus study finds little benefit to repurposed HIV drug
March 18, 2020
Sage redraws its plans for failed antidepressant drug
March 18, 2020
Pharma salesforces brought to a halt as coronavirus shutters economy
March 17, 2020
Germany's CureVac, the subject of a reported US overture, thrust into coronavirus spotlight
March 16, 2020
With AbCellera deal, Lilly becomes latest pharma to start coronavirus program
March 13, 2020
CureVac CEO replaced in midst of biotech's coronavirus push
March 12, 2020
Facing coronavirus risk, a top cancer group postpones annual meeting
March 11, 2020
2 newer multiple myeloma drugs fall short in bid for wider market
March 10, 2020
As US coronavirus cases mount, top drugmakers tell employees to work from home
March 9, 2020
Coronavirus spread threatens spring slate of medical meetings
March 6, 2020
A closer look at the Ebola drug that's become the top hope for a coronavirus treatment
March 5, 2020
In a CRISPR first, Editas therapy used to fix genes in the body
March 4, 2020
High prices fuel pharma profits. New research provides more context
March 3, 2020
Sanofi wins US approval for myeloma drug key to its cancer ambitions
March 2, 2020
Cell therapy developer Unum restructures, cutting staff in pivot
March 2, 2020
Karyopharm shares jump on positive study data for multiple myeloma drug
March 2, 2020
FDA reports first drug shortage due to coronavirus impact
Feb. 28, 2020
Gilead commits to in-house development of coronavirus treatment hopeful
Feb. 27, 2020
Amgen heart drug passes interim check, setting up year-end readout
Feb. 26, 2020
US begins first study of coronavirus treatment, testing Gilead's remdesivir
Feb. 25, 2020
As shortages draw spotlight, Sanofi to spin out drug ingredient business
Feb. 24, 2020
Chinese biotech enlists GSK in coronavirus vaccine effort
Feb. 24, 2020
With supply tight, Novartis readies gene therapy plant for production
Feb. 21, 2020
GSK taps Immatics' cell therapy science in research deal
Feb. 20, 2020
Tocagen restructuring leads to reverse merger with Forte
Feb. 20, 2020
Biotech executives, having pledged fair pricing, criticize drugmaker for steep hike
Feb. 19, 2020
Audentes to spend $110M on new gene therapy plant in North Carolina
Feb. 18, 2020
Sanofi starts work on coronavirus vaccine, bringing scale to global research effort
Feb. 18, 2020
Bristol-Myers finds FDA receptive to speedy review of key cell therapy
Feb. 13, 2020
J&J bolsters coronavirus vaccine work with BARDA partnership
Feb. 12, 2020
Sanofi shrinks executive team as new CEO reshapes French drugmaker
Feb. 12, 2020
Moderna, raising cash, quickly advances coronavirus candidate
Feb. 11, 2020
Biohaven misses a chance to prove it's more than migraine
Feb. 10, 2020
AbbVie's plan to replace Humira is ahead of schedule
Feb. 7, 2020
In small study, hints of promise for 'natural killer' cell therapy
Feb. 6, 2020
Kite isn't flying with investors, and Gilead knows it
Feb. 5, 2020
Regeneron partners with US government to develop coronavirus treatment
Feb. 4, 2020
Antiviral drugmakers GSK, Gilead join fight against coronavirus' spread
Feb. 3, 2020
Biotech lacking diverse leadership, top trade group admits
Jan. 31, 2020
Vertex impresses with strong Trikafta launch
Jan. 30, 2020
Novartis gives up on Advair generic, leaving Mylan as sole competitor
Jan. 29, 2020
Zolgensma sales grow, signaling gene therapy momentum
Jan. 29, 2020
FDA, expecting a gene therapy boom, firms up policies
Jan. 28, 2020
J&J launches vaccine efforts as coronavirus spreads
Jan. 27, 2020
Epizyme drug granted approval by FDA for rare cancer
Jan. 23, 2020
AstraZeneca pledges to go 'carbon negative' by 2030
Jan. 23, 2020
Drug trial success a consolation prize for Akcea, Ionis
Jan. 22, 2020
5 biopharmas to watch as the decade's last earnings kick off
Jan. 21, 2020
BioNTech rescues cancer biotech Neon in bargain buyout
Jan. 16, 2020
Lilly expands half-price insulin offerings
Jan. 15, 2020
Nationwide Children's, a gene therapy leader, launches manufacturing spinout
Jan. 15, 2020
Incyte turns to German Morphosys to refresh cancer pipeline
Jan. 13, 2020
A biotech startup launches with unusual goal: invent new drugs, and sell them for less
Jan. 13, 2020
Blueprint wins 1st FDA approval with targeted cancer drug
Jan. 10, 2020
5 biotech trends to follow in 2020
Jan. 9, 2020
Belgian CDMO Ardena gets new private equity owners
Jan. 9, 2020
US cancer death rate drops by most on record
Jan. 8, 2020
Trial failure keeps Incyte searching for its next act
Jan. 3, 2020
Stealth's rare disease drug falls short in study, sinking shares
Dec. 20, 2019
Bladder cancer approval gives Seattle Genetics its second drug
Dec. 19, 2019
Trump administration lays out plans to import drugs from abroad
Dec. 18, 2019
GSK advances blood cancer drug to FDA, but rivals threaten
Dec. 17, 2019
Roche's $4.8B deal for Spark cleared by FTC after long delay
Dec. 16, 2019
BioMarin drug for dwarfism meets goal in late-stage study
Dec. 16, 2019
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Dec. 12, 2019
Novartis still hasn't solved its CAR-T manufacturing issues
Dec. 11, 2019
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
Dec. 10, 2019
New drugs for sickle cell excite but, at ASH, a recognition that more is needed
Dec. 9, 2019
Drug Launch of the Year: Zolgensma
Dec. 9, 2019
Executive of the Year: Josh Bilenker, Loxo Oncology
Dec. 9, 2019
Sangamo keeps pressure on rivals with updated hemophilia data
Dec. 7, 2019
Myeloma cell therapies, now in pharma hands, move into spotlight
Dec. 7, 2019
Trial setback strikes blow to Sage antidepressant ambitions
Dec. 5, 2019
Lilly puts its cancer future in Loxo's hands
Dec. 5, 2019
Astellas joins gene therapy race with $3B Audentes buy
Dec. 3, 2019
FDA denies Lexicon bid to reverse diabetes drug rejection
Dec. 2, 2019
Wave faces key test in bid to challenge Sarepta in DMD
Nov. 27, 2019
Karuna's 'A-ha moment': A billion-dollar stock swing and new expectations
Nov. 26, 2019
Medicines Co. deal caps pharma's reentry into field it once abandoned
Nov. 26, 2019
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Nov. 24, 2019
'I believe the drug works.' Biogen CMO defends decision to submit Alzheimer's drug to FDA
Nov. 22, 2019
AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron
Nov. 21, 2019
Takeda sees cell, gene therapy in its future. Is it too late?
Nov. 20, 2019
First look at CRISPR, Vertex gene-editing therapy hints at treatment potential
Nov. 19, 2019
Teva to restart production of cancer drug after shortages stressed treatment
Nov. 14, 2019
Sage's new drug starts slow, as Wall Street waits for depression data
Nov. 13, 2019
FDA documents appear to clear Amarin path to wider heart drug approval
Nov. 12, 2019
Regenxbio, stung by trial hold on gene therapy, sues FDA
Nov. 11, 2019
FDA approves first drug for anemia tied to rare blood disorder
Nov. 8, 2019
AnaptysBio shares collapse after 'worst case scenario' for key drug
Nov. 8, 2019
Trump administration sues Gilead over HIV drug patents
Nov. 7, 2019
Biogen broadens biosimilar bet to go after top-selling eye drugs
Nov. 6, 2019
Regeneron defends bid to challenge Merck in lung cancer
Nov. 5, 2019
China approves Alzheimer's drug, inviting fresh debate in field with few successes
Nov. 4, 2019
Stephen Hahn, top MD Anderson official, will be next FDA chief
Nov. 1, 2019
Roivant, Sumitomo alliance to target cystic fibrosis gene therapy
Oct. 31, 2019
FDA panel backs withdrawal of Amag drug to prevent preterm birth
Oct. 30, 2019
Strong sales buoy pharma even as risks grow
Oct. 29, 2019
Mirati keeps pace with Amgen in hunt for KRAS cancer drug
Oct. 28, 2019
Gilead CAR-T sales slow, renewing growth doubts
Oct. 25, 2019
J&J cuts profits to account for proposed opioid settlement
Oct. 24, 2019
7 questions on Biogen's revival of a failed Alzheimer's drug
Oct. 22, 2019
Seattle Genetics stock hits record high on well-placed breast cancer bet
Oct. 21, 2019
Mirati data to test whether biotech can challenge Amgen in KRAS quest
Oct. 18, 2019
Lilly cancer drug pipeline hit by trial setback
Oct. 16, 2019
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Oct. 15, 2019
Revance CEO stepping down over 'misjudgment'
Oct. 14, 2019
Lilly's 1-drug migraine business gets support with new approval
Oct. 11, 2019
Gene therapy biotechs caught in manufacturing crunch
Oct. 10, 2019
Australian drugmaker's decade-long journey ends in FDA approval
Oct. 9, 2019
With new report, ICER puts itself at center of drug pricing storm
Oct. 8, 2019
Buttigieg targets pharma in aggressive plan to lower drug prices
Oct. 7, 2019
Arbutus stops early hepatitis B study on safety concerns
Oct. 4, 2019
J&J paying $20M to settle Ohio opioid suits
Oct. 2, 2019
Novartis, Microsoft ink 5-year AI alliance
Oct. 2, 2019
Sanofi's story needs to be 'better told,' new CEO says
Oct. 1, 2019
Seattle Genetics makes case it can be more than Adcetris
Sept. 30, 2019
Novartis, Lilly drugs set new survival bar in breast cancer
Sept. 29, 2019
Colon cancer proves tougher target for Amgen's KRAS drug
Sept. 28, 2019
Cancer immunotherapy boom showing no sign of slowdown
Sept. 27, 2019
FDA warning slowed immunotherapy use in bladder cancer
Sept. 25, 2019
Novartis to speed AveXis integration in wake of data manipulation
Sept. 24, 2019
States pull back curtain on drug prices, to uncertain effect
Sept. 23, 2019
With eye to competition, Biogen explores higher doses of Spinraza
Sept. 20, 2019
Novartis, shadowed by data scandal, renews case for Zolgensma
Sept. 19, 2019
In first, cancer drugs simultaneously approved in US, Canada, Australia
Sept. 18, 2019
Alexion's CFO steps down in surprise departure
Sept. 18, 2019
Ebola vaccine from Merck takes step toward US approval
Sept. 17, 2019
5 questions ESMO cancer drug data might answer
Sept. 16, 2019
Novartis' strong MS results could pose challenge to Roche
Sept. 13, 2019
Moderna marks progress toward goal of coaxing medicine from body's cells
Sept. 12, 2019
Sanofi paying Lexicon $260M to exit diabetes alliance
Sept. 11, 2019
Biomarker data help Merck case for wide use of Keytruda combo
Sept. 10, 2019
After scandal, Novartis pledges faster action on data integrity
Sept. 9, 2019
Cancer drug data back up Lilly's Loxo buyout
Sept. 9, 2019
Amgen update shows promise, limits of KRAS cancer drug
Sept. 8, 2019
MD Anderson official emerges as top choice to run FDA, reports say
Sept. 6, 2019
With third pharma deal, IFM's unorthodox approach paying off
Sept. 5, 2019
Novartis secures NICE nod for Luxturna with discount offer
Sept. 4, 2019
UniQure stays a step ahead in hemophilia B
Sept. 3, 2019
Alexion shares slide on Amgen patent challenge to top-seller
Aug. 30, 2019
Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters
Aug. 30, 2019
Amgen patents on Repatha invalid, judge rules in reversal
Aug. 28, 2019
Purdue offering as much as $12 billion to settle opioid claims: report
Aug. 28, 2019
Oklahoma judge orders J&J pay $572M in landmark opioid case
Aug. 26, 2019
Lilly's case for Taltz helped by expanded approval
Aug. 26, 2019
Amgen buying Celgene's Otezla in $13B deal
Aug. 26, 2019
Moving quickly, GSK to advance myeloma drug on new data
Aug. 23, 2019
HHS to fund further manufacturing of Merck Ebola vaccine
Aug. 22, 2019
As supply shortages persist, ADMA relaunches immune globulin drug
Aug. 22, 2019
Trump administration not giving up on plan to require prices in TV drug ads
Aug. 21, 2019
AstraZeneca lung cancer miss is Merck's gain
Aug. 21, 2019
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Aug. 19, 2019
Celgene wins approval for drug key to Bristol buyout
Aug. 16, 2019
Novo faces shareholder suit over insulin sales disclosures
Aug. 16, 2019
Roche cancer drug the 3rd approved for pan-tumor use
Aug. 15, 2019
Study success strengthens case for Lynparza in ovarian cancer
Aug. 14, 2019
Novartis replaced AveXis chief scientist, R&D head amid Zolgensma uproar
Aug. 14, 2019
Lawmakers up pressure on Novartis in wake of data manipulation
Aug. 13, 2019
Amgen resurgent as court victory for top drug eases doubts
Aug. 12, 2019
In rebuke of Novartis, FDA making 'statement for the world'
Aug. 9, 2019
FDA decision on Amarin heart drug delayed as agency to hold expert review
Aug. 8, 2019
Medicare boosts CAR-T cancer therapies with expanded coverage
Aug. 8, 2019
Novartis CEO on defense as data scandal clouds gene therapy approval
Aug. 7, 2019
Novartis used manipulated data in winning Zolgensma approval, FDA says
Aug. 6, 2019
Novo buys North Carolina plant from Purdue
Aug. 6, 2019
In reversal, Mallinckrodt puts split plans on hold
Aug. 6, 2019
Roche trial win for Tecentriq leaves questions unanswered
Aug. 5, 2019
Congress is going after drug prices. Pharma CEOs aren't panicking, yet
Aug. 2, 2019
Akorn takes $74 million charge to settle shareholder lawsuit
Aug. 1, 2019
Sales gap grows between rival Merck, Bristol cancer therapies
July 30, 2019
Lilly cancer push boosted by survival benefit to key drug
July 30, 2019
Big pharma deals show industry's weak spots
July 29, 2019
Sanofi writes down hemophilia drug as competitive pressures rise
July 29, 2019
J&J advances MS drug candidate toward US, EU markets
July 26, 2019
Editas, Allergan launch first in vivo study of CRISPR-based medicine
July 25, 2019
Bristol-Myers hits snag in plan to catch Merck in lung cancer
July 24, 2019
In pivot, Sage turns focus to treatment-resistant depression
July 24, 2019
Acadia schizophrenia trial misses goal, setting back pipeline hopes
July 23, 2019
5 questions going into this week's biopharma earnings
July 22, 2019
ViiV veteran science chief to step down
July 19, 2019
Catalent to help make Novartis' Zolgensma at Maryland site
July 18, 2019
Novartis gives first glimpse at Zolgensma launch
July 18, 2019
Inovio cuts staff, research to buy time
July 17, 2019
Novartis secures speedy review for sickle cell drug
July 16, 2019
Neon to advance cancer vaccine after early results suggest added benefit
July 15, 2019
Gilead forges closer ties with Galapagos in $5.1B deal
July 14, 2019
Lilly's Shaw to head Gilead's cancer push as new CEO of Kite
July 11, 2019
German court blocks sale of Sanofi, Regeneron cholesterol drug
July 11, 2019
White House pulls drug rebate rule to relief of payers
July 11, 2019
Amgen's KRAS success has other drugmakers eager to follow
July 10, 2019
Hunting better biomarkers, J&J taps Celsius to unpack role played by single cells
July 9, 2019
Pharma stocks slide as industry mulls Trump drug price action
July 9, 2019
Zolgensma set a new drug pricing bar. Insurers show some signs of pushback
July 3, 2019
Gilead firms up path to market for key arthritis drug
July 2, 2019
Bayer backs cell therapy startup with $215M in funding
July 1, 2019
Amgen bone drug application knocked back in Europe
June 28, 2019
Former FDA head Gottlieb joins Pfizer board
June 27, 2019
Catalent picks up Novavax facilities, 100 employees
June 27, 2019
Samsung Bioepis CEO urges patience as US biosimilar market lags
June 26, 2019
AbbVie buying Allergan in $63B deal for its post-Humira future
June 25, 2019
Roche wins speedy OK for lymphoma drug Polivy
June 11, 2019
Experimental drug delays Type 1 diabetes in research first
June 10, 2019
Vertex sets sights on DMD gene therapy, joining crowded field
June 7, 2019
Former GSK site to be redeveloped as WeWork-styled life sciences center
June 6, 2019
Opioid maker Insys to pay $225M to settle fraud charges
June 6, 2019
3 takeaways from cancer's biggest conference
June 5, 2019
Bristol-Myers shuffles executive ranks for post-Celgene future
June 5, 2019
Biotech, pharma stocks climb higher after cancer meeting
June 4, 2019
Bluebird gene therapy approved in Europe in first for severe blood disorder
June 3, 2019
Blueprint keeps pressure on Lilly with RET-targeted cancer therapy
June 3, 2019
Early cancer drug data give Amgen hope it has 'cracked KRAS code'
June 3, 2019
At cancer conference, debate over speedy drug approvals in the spotlight
June 3, 2019
For some lung cancer patients, Keytruda provides lasting benefit
June 1, 2019
Novartis breast cancer drug shows survival benefit in younger women
June 1, 2019
Turning Point makes push to outdo Pfizer, Roche in targeted cancer therapy
May 31, 2019
Follow-up studies often lacking for cancer drugs approved early
May 29, 2019
Novartis gene therapy approved, but will come at cost of more than $2M
May 24, 2019
Nektar forms new biotech to sell under-review pain drug
May 24, 2019
Dynavax cuts staff in retreat from cancer research
May 24, 2019
Novartis looking earlier for deals as biotech valuations stay high
May 23, 2019
Verily lures major pharmas with promise of speedier clinical research
May 21, 2019
ICER seeks to make drug price research more accessible
May 20, 2019
Gilead CEO pressured on PrEP pricing at House hearing
May 17, 2019
FDA schedules Aimmune's peanut allergy drug for September expert review
May 16, 2019
Biotech in the spotlight at ASCO as pharma takes back seat
May 16, 2019
Vertex follows pharma lead in bet on protein degradation
May 15, 2019
Myovant reports a Phase 3 success, but Wall Street isn't cheered
May 14, 2019
Pharma, late to digital game, rushes to catch up
May 13, 2019
Catalent, hindered by Softgel weakness, sees stronger growth ahead
May 9, 2019
Nearing gene therapy launch, Bluebird cautions a slower start
May 9, 2019
Drugmakers will soon be required to disclose prices in TV ads
May 8, 2019
AstraZeneca blood cancer drug hits study goal early
May 7, 2019
'Pathbreaking' Ionis trial offers way forward in Huntington's disease
May 6, 2019
Trelegy success gives GSK some respiratory respite
May 3, 2019
Renewable energy to power all Novo drug production by next year
May 2, 2019
Alnylam posts strong Onpattro sales as competition heats up
May 2, 2019
Longtime Gilead finance chief Robin Washington to step down next year
May 1, 2019
At gene therapy meeting, insurance execs grapple with expected cost
April 30, 2019
Keytruda powers Merck to another strong quarter
April 30, 2019
Praluent scores heart label, matching Amgen's rival Repatha
April 29, 2019
Cancer drugs lift AstraZeneca, aiding turnaround
April 26, 2019
Novartis chief defends cell, gene therapy push
April 24, 2019
In R&D, small biotechs hold their own against big pharma
April 23, 2019
Keytruda approved in kidney cancer, challenging Bristol-Myers
April 22, 2019
Roche's pharma business is booming, for now
April 17, 2019
With FDA decision near, Novartis bolsters SMA gene therapy case
April 16, 2019
J&J drugs sales outperform despite generic hit
April 16, 2019
Allergan wins support of influential advisory firms in shareholder fight
April 15, 2019
J&J wins FDA OK for first targeted therapy in bladder cancer
April 12, 2019
Bristol-Myers wins shareholder backing for Celgene buyout
April 12, 2019
Lonza's CEO on keeping up with microbiome, gene therapy boom
April 11, 2019
Unblinded: Hervé Hoppenot on solving Incyte's 'single asset syndrome'
April 10, 2019
Alcon spin-out marks step in Novartis plan to remake business
April 9, 2019
Coherus' Neulasta biosimilar surprises with strong early uptake
April 8, 2019
Pfizer wins expanded Ibrance approval using real world data
April 5, 2019
Amgen, Novartis clash in dispute over Aimovig partnership
April 4, 2019
AARP report offers window into generic drugmaker pain
April 4, 2019
Sangamo hemophilia A progress boosts shares
April 2, 2019
Despite research boom, few immunotherapy studies targeting pancreatic cancer
April 1, 2019
Early studies hint at some potential for CAR-T therapy in solid tumors
March 31, 2019
AstraZeneca inks ambitious $6.9B deal for Daiichi cancer therapy
March 29, 2019
Gilead earns needed trial win as arthritis drug succeeds in 2 studies
March 28, 2019
Sarepta to seek speedy approval of third DMD drug
March 28, 2019
Novartis wins key US approval for multiple sclerosis drug Mayzent
March 27, 2019
A year after FDA refusal, Celgene resubmits ozanimod for review
March 26, 2019
Activist investor escalates pressure on Allergan
March 25, 2019
Aducanumab's failure puts pressure on field to look beyond amyloid
March 22, 2019
FDA's Gottlieb defends agency response to valsartan contamination
March 21, 2019
Soon to depart, Scott Gottlieb keeps focus on greater drug competition
March 20, 2019
Roche's Tecentriq secures another immunotherapy first
March 19, 2019
Gene therapy progress spurs competition in biotech buyouts
March 19, 2019
Heart benefits to AstraZeneca's Farxiga detailed in new findings
March 18, 2019
FDA's Gottlieb calls for greater adoption of new clinical trial tools
March 15, 2019
Celgene dodges Alvogen bid to overturn Revlimid patent
March 14, 2019
Amgen's top-selling Enbrel in balance as key court ruling nears
March 13, 2019
NCI Director Ned Sharpless to become acting FDA commissioner
March 12, 2019
Biogen sells biologics plant to Fujifilm in $890M deal
March 12, 2019
Roche wins first immunotherapy approval for triple-negative breast cancer
March 8, 2019
Mylan's Advair generic pressures GSK with strong launch
March 8, 2019
FDA walks back plan to alter generic names of already approved biologics
March 7, 2019
Allergan depression drug fails in setback for turnaround
March 7, 2019
FDA approves J&J's esketamine as faster-acting depression treatment
March 6, 2019
Gilead oncology chief departing to head up Glenmark spin-out
March 5, 2019
FDA Commissioner Scott Gottlieb resigning, to leave in one month
March 5, 2019
Celgene checks regulatory box for key drug in Bristol-Myers deal
March 5, 2019
Lilly to launch generic of its insulin Humalog, cutting list price in half
March 4, 2019
Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear
March 1, 2019
Roche wins US approval of more convenient Herceptin
March 1, 2019
At Senate hearing, pharma shows split on biosimilars
Feb. 27, 2019
Gene therapy progress spurs Sarepta buy of Myonexus
Feb. 27, 2019
Pharma's day in Congress: 'A hearing not a show'
Feb. 26, 2019
In front of Congress, pharma execs blame 'broken' system
Feb. 26, 2019
Amgen wins jury verdict in PCSK9 court battle with Sanofi, Regeneron
Feb. 25, 2019
In gene editing milestone, first patient treated in Vertex, CRISPR Therapeutics study
Feb. 25, 2019
How lawmakers could pressure top pharma execs in Senate hearing
Feb. 25, 2019
Insulin drugmakers again come under Senate scrutiny
Feb. 22, 2019
In unusual step, FDA pushes back against reports on questionable generic drug quality
Feb. 22, 2019
FDA to accept drug plant inspections by Poland, Slovenia
Feb. 21, 2019
Sanofi handed payers nearly $12B in drug rebates last year
Feb. 21, 2019
Allergan rebuffs activist call to split CEO, chairman roles
Feb. 20, 2019
Intercept NASH drug succeeds in field's first positive Phase 3 trial
Feb. 19, 2019
Hunt for immunotherapy combinations turns up success in kidney cancer
Feb. 16, 2019
As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi
Feb. 15, 2019
Teva set to shed 11 manufacturing sites in 2019
Feb. 14, 2019
DBV sets sights on FDA resubmission for peanut allergy treatment
Feb. 14, 2019
Teva predicts bleak year ahead as generic, Copaxone sales drop
Feb. 13, 2019
J&J's esketamine wins backing of key advisory panel
Feb. 12, 2019
Merck kidney cancer data impresses, putting pressure on Bristol-Myers
Feb. 12, 2019
Celgene's Revlimid defenses withstand another challenge
Feb. 12, 2019
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Feb. 11, 2019
Sangamo setback pulls down gene editing biotech peers
Feb. 8, 2019
Sanofi turns R&D focus inward amid cuts to drug pipeline
Feb. 7, 2019
Pharma CEOs to testify in Senate drug pricing hearing
Feb. 6, 2019
Gilead investors hold their breath as trial readouts near
Feb. 5, 2019
'Strategic fit' with Bristol-Myers kept Celgene from casting wider net in deal negotiations
Feb. 1, 2019
Trump administration proposal takes aim at drug rebates
Jan. 31, 2019
Lonza promotes biopharma head to CEO spot
Jan. 31, 2019
Pharma misses its prescription for growth
Jan. 31, 2019
Roche Alzheimer's setback puts Biogen in lonely spot
Jan. 30, 2019
Pfizer faces 2019 burdened by competitive challenges
Jan. 29, 2019
Amgen's migraine lead faces early test in CVS decision
Jan. 28, 2019
Lonza begins second-gen supply of Portola's Andexxa
Jan. 24, 2019
Opdivo questions hang over Bristol-Myers amid sales miss
Jan. 24, 2019
High-ranking Vertex exec fired over code of conduct violations
Jan. 23, 2019
Editas' CEO exit sparks investor fears
Jan. 22, 2019
J&J sales forecast disappoints as generic, pricing headwinds rise
Jan. 22, 2019
Aimmune drug application confusion leaves investors searching for answers
Jan. 18, 2019
7 biopharma trends to watch in 2019
Jan. 17, 2019
Allergan, Mohawk tribe ask for Supreme Court review of scrutinized patent case
Jan. 16, 2019
FDA review of Aimmune drug put on hold due to government shutdown
Jan. 14, 2019
Hunting productivity, drugmakers pitch new 'pillars' of R&D
Jan. 11, 2019
The winners and losers from JPM 2019
Jan. 11, 2019
A biotech's M&A invitation and Editas' next CRISPR step
Jan. 10, 2019
Moderna's defense, biosimilar battles and other updates
Jan. 9, 2019
Shire deal done, Takeda turns to task of forging top pharma
Jan. 9, 2019
Novartis' cell therapy ambitions outpace early returns
Jan. 7, 2019
Sanofi zeroes in on bispecifics in reworked Regeneron deal
Jan. 7, 2019
Bristol-Myers' gamble on Celgene pipeline prospects
Jan. 4, 2019
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Jan. 3, 2019
Drugmakers open new year with price increases on dozens of medicines
Jan. 2, 2019
Acorda wins FDA nod for Parkinson's drug
Dec. 24, 2018
Our 10 best stories of 2018
Dec. 21, 2018
Gene therapy could be cost effective in SMA, but not at $4M
Dec. 21, 2018
Novartis seeks to acquire French CAR-T contract manufacturer
Dec. 20, 2018
Pharma returns on R&D ebb to new low, Deloitte finds
Dec. 20, 2018
Trump drug ad proposal earns support from insurers, medical groups
Dec. 19, 2018
GSK, Pfizer to launch consumer joint venture in market-shifting partnership
Dec. 19, 2018
AstraZeneca's China push boosted by anemia drug OK
Dec. 18, 2018
AbbVie shows allure of pharma stock buybacks
Dec. 14, 2018
Mylan patent win for Lantus copy looks unlikely to speed market entry
Dec. 13, 2018
Kaléo, facing criticism, launches generic overdose treatment at cut price
Dec. 12, 2018
Bausch bids $200M for Synergy gut drug, eyeing turnaround opportunity
Dec. 12, 2018
Roche wins key cancer drug approval, but taking on Merck remains a challenge
Dec. 11, 2018
Gilead names Roche veteran O'Day as CEO
Dec. 10, 2018
ASH successes set to lift Imbruvica in CLL
Dec. 6, 2018
In CAR-T, manufacturing a hurdle Novartis has yet to clear
Dec. 6, 2018
At ASH, bispecific cancer therapies make a mark
Dec. 5, 2018
ASH18: Bluebird's gene therapy progress shadowed by MDS case
Dec. 4, 2018
Pharma of the Year: Merck & Co.
Dec. 3, 2018
Innovation of the Year: RNA-targeting therapies
Dec. 3, 2018
Executive of the Year: Emma Walmsley, GlaxoSmithKline
Dec. 3, 2018
ASH18: CAR-T shows up in early CLL test
Dec. 2, 2018
ASH18: Cancer drug trials in need of modernization, NCI director says
Dec. 1, 2018
ASH18: Trial successes back Celgene belief in luspatercept
Dec. 1, 2018
Changing markets: A look at rheumatoid arthritis
Nov. 30, 2018
Bayer to cut 12,000 jobs in overhaul of business
Nov. 29, 2018
Alkermes' schizophrenia drug succeeds in needed trial win
Nov. 29, 2018
Outcry over gene-edited babies grows as Chinese researcher defends work
Nov. 28, 2018
Loxo cancer drug wins US approval in advance for targeted therapy
Nov. 27, 2018
Drugmakers vie to capture slice of rheumatoid arthritis market
Nov. 26, 2018
Gene-edited babies born in China, Chinese researcher claims
Nov. 26, 2018
Mylan taken to task for manufacturing failings at key plant
Nov. 21, 2018
Sage faces delayed decision on postpartum depression drug
Nov. 20, 2018
Pfizer tests Trump with plans to hike prices on 41 drugs
Nov. 16, 2018
At SITC, clear wins for immunotherapy combos remain elusive
Nov. 12, 2018
NASH drugs come into focus as field awaits late-stage data
Nov. 9, 2018
AstraZeneca at 'inflection point' in turnaround, predicts CEO
Nov. 8, 2018
5 election takeaways for pharma
Nov. 7, 2018
Nektar lures Pfizer with promise of combo immunotherapy
Nov. 6, 2018
Humira biosimilar discounting 'aggressive' as competition enters in Europe
Nov. 2, 2018
Alkermes depression drug approval odds slim after negative FDA panel vote
Nov. 2, 2018
Gilead's stock wobbles on HIV pricing concerns
Nov. 1, 2018
Shingrix gives GSK a near-term boost
Nov. 1, 2018
Novartis wins US nod for Humira biosimilar, but focus now on Europe
Oct. 31, 2018
Come January, will pharma pricing pledges hold?
Oct. 31, 2018
Merck's Keytruda secures broader lung cancer approval
Oct. 31, 2018
Alkermes' depression drug set to test flexibility of FDA
Oct. 29, 2018
Pfizer, Novartis partner in hunt to find drugs for NASH
Oct. 29, 2018
Esperion clears final trial hurdle in bid to shake up cholesterol market
Oct. 28, 2018
Amgen, Regeneron appear most at risk from Trump's latest pricing plan
Oct. 26, 2018
Trump pitches new plan to bring US drug prices down
Oct. 25, 2018
Keytruda growth fuels Merck investment
Oct. 25, 2018
Biogen dips as BAN2401 data bring more questions than answers
Oct. 25, 2018
Amgen cuts US Repatha price 60% amid market pressure
Oct. 24, 2018
DTC's big issues: Trump, cancer drugs and the First Amendment
Oct. 24, 2018
Reimbursement lags cancer drug approvals, but some European countries wait longer
Oct. 24, 2018
Pfizer, Lilly avoid safety red flags in late-stage tanezumab trial
Oct. 24, 2018
Advair copy approval 'imminent,' Mylan says, but investors jittery
Oct. 23, 2018
Viagra no more: The changing face of drug ads on TV
Oct. 22, 2018
ESMO 2018: What you missed over the weekend
Oct. 22, 2018
Loxo's targeted therapy holds up to Roche challenge
Oct. 20, 2018
Benefit of Roche's Tecentriq looks limited in breast cancer
Oct. 20, 2018
Clovis aims at new market for cancer drug Rubraca
Oct. 19, 2018
Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Oct. 18, 2018
Humira biosimilars launch in Europe, testing AbbVie
Oct. 17, 2018
Biosimilars bite into Herceptin in Europe
Oct. 17, 2018
5 questions on the Trump admin's bid to mandate prices in drug ads
Oct. 16, 2018
Confronting pharma, Trump admin seeks price disclosure in drug ads
Oct. 15, 2018
Under pressure, drugmakers give an inch on DTC drug ads
Oct. 15, 2018
Opdivo misses survival goal in small-cell lung cancer study
Oct. 12, 2018
Expansion gives Almac room to grow in North Carolina
Oct. 11, 2018
US tightens scrutiny of foreign investment into biotech sector
Oct. 11, 2018
Price increases on top drugs drove majority of recent growth, analysis finds
Oct. 10, 2018
Trevena shares sink on FDA concerns ahead of key panel meeting
Oct. 9, 2018
Loxo, Blueprint drive forward with RET-targeting cancer therapies
Oct. 8, 2018
FDA clears rare disease therapy from Akcea, Ionis
Oct. 5, 2018
Gilead reaches deal for Yescarta coverage in England
Oct. 5, 2018
Sarepta gene therapy for DMD takes another step forward
Oct. 4, 2018
Roche drug shows benefit in spinal muscular atrophy
Oct. 3, 2018
In reversal, GSK to restart limited payments to doctors
Oct. 3, 2018
Rare case of CAR-T resistance underscores manufacturing hurdles
Oct. 2, 2018
10 biotechs set to shake up the industry's top ranks
Oct. 1, 2018
Pfizer's Bourla to succeed Read as CEO
Oct. 1, 2018
What you need to know about continuous manufacturing
Oct. 1, 2018
Regeneron wins early approval for cancer immunotherapy
Sept. 29, 2018
Alnylam puts its chips on speedy OK for rare disease drug
Sept. 28, 2018
Cancer drug approval expands Pfizer's targeted therapy ambition
Sept. 28, 2018
Lilly's migraine drug wins US approval, pressuring rivals Amgen, Teva
Sept. 27, 2018
Merck CEO to stay on through 2019
Sept. 26, 2018
AstraZeneca's Imfinzi shows its strength in Stage 3 lung cancer
Sept. 25, 2018
Tecentriq sets the bar in small-cell lung cancer
Sept. 25, 2018
Pharma's slow embrace of continuous manufacturing
Sept. 24, 2018
Foundation Med advances liquid biopsy ambition with new test
Sept. 24, 2018
Amicus expands into gene therapy with $100M deal
Sept. 20, 2018
AbbVie accused of 'far-reaching' kickback scheme for Humira
Sept. 18, 2018
Viking shares soar as NASH drug impresses
Sept. 18, 2018
Will Ajovy lead Teva's turnaround?
Sept. 17, 2018
Teva wins much-needed US approval of migraine drug
Sept. 14, 2018
Allergan's Bonti buy part of plan to double medical aesthetics business
Sept. 14, 2018
Sanofi looks to China in business restructure
Sept. 13, 2018
Boehringer bets on oncolytic viruses in ViraTherapeutics deal
Sept. 13, 2018
Gottlieb rebuffs pharma CEO who claimed price hikes were 'moral requirement'
Sept. 12, 2018
Bristol-Myers' psoriasis drug proves itself in mid-stage study
Sept. 12, 2018
Alcon to shift HQ to Switzerland after Novartis spinoff
Sept. 11, 2018
Appeals court upholds CRISPR patent ruling in win for Broad Institute
Sept. 10, 2018
FDA closes door to speedy OK for Amicus rare disease drug
Sept. 10, 2018
GSK's pitch for Nucala in COPD turned down by FDA
Sept. 7, 2018
Invokana gains heart labeling in Europe
Sept. 7, 2018
GSK eliminates 650 jobs amid R&D revamp
Sept. 6, 2018
Portola inches closer to large-scale Andexxa production
Sept. 6, 2018
BioMarin pumps $43M into Ireland drug plant
Sept. 6, 2018
FDA delays key Tecentriq decision by 3 months
Sept. 6, 2018
Sangamo pitches gene therapy progress, yet investors stay skeptical
Sept. 5, 2018
Chi-Med wins landmark cancer drug approval in China
Sept. 5, 2018
Mannkind stays afloat with United licensing deal
Sept. 4, 2018
Pfizer calls out pharma peers for 'scare tactics' on biosimilars
Aug. 29, 2018
UK's NICE judges Yescarta too pricey, dealing blow to Gilead
Aug. 28, 2018
FDA confronts its limits in push on drug pricing
Aug. 27, 2018
Pfizer's tafamidis cuts risk of death in rare disease study
Aug. 27, 2018
Esperion clears another milestone in bet on cholesterol pill
Aug. 27, 2018
Lawmakers push to require price disclosure in DTC drug ads
Aug. 24, 2018
Novartis' trial success revives PI3K potential in breast cancer
Aug. 23, 2018
AbbVie brings Argenx drug onboard amid immuno-oncology push
Aug. 22, 2018
HHS touts drug pricing 'wins,' but true tests still to come
Aug. 21, 2018
Aimovig launch bolsters hopes for blockbuster sales
Aug. 20, 2018
Amicus secures US approval for Fabry disease drug
Aug. 10, 2018
In first, FDA approves RNA interference drug from Alnylam
Aug. 10, 2018
CVS rejects pharma claim that rebates push up drug prices
Aug. 9, 2018
AstraZeneca settles Texas suits claiming it mismarketed Crestor, Seroquel
Aug. 8, 2018
Mylan to explore its options as North American business struggles
Aug. 8, 2018
Express Scripts drops Mavyret from 2019 formulary in blow to AbbVie
Aug. 7, 2018
Spark sheds $1B in value on hemophilia gene therapy data
Aug. 7, 2018
Regeneron expands immuno-oncology push with Bluebird pact
Aug. 6, 2018
Drugs make up more US health spending than thought, report suggests
Aug. 3, 2018
AbbVie surprised investors with its hepatitis C success. Will it last?
Aug. 2, 2018
Latest PRV sale further evidence of sliding value
Aug. 2, 2018
Gilead spotlights Truvada ads as preventive use grows
Aug. 1, 2018
Pfizer CEO sees drug rebates 'going away' in US
July 31, 2018
RedHill drug for Crohn's clears first Phase 3 hurdle
July 30, 2018
AbbVie faith in Humira, future growth remains ironclad
July 27, 2018
Sales of Roche new drugs are surging. Will that be enough?
July 26, 2018
Positive Alzheimer's results from Biogen, Eisai spark 'cautious optimism'
July 25, 2018
GSK secures US approval of new malaria drug
July 25, 2018
Two-drug HIV regimen from GSK bolstered by Phase 3 data
July 24, 2018
Seeking to adopt AI, drugmakers search for right mix of talent
July 23, 2018
Sangamo to buy TxCell, cell therapy tech in $84M deal
July 23, 2018
7 companies to watch during Q2 earnings
July 19, 2018
Novartis hits CAR-T manufacturing snag as Kymriah sales disappoint
July 19, 2018
Tecentriq misses another chance to catch Keytruda
July 19, 2018
Drug lobby aims to shake up how medicines are paid for
July 18, 2018
Novartis points to price hike pause, potentially dodging Pfizer fate
July 18, 2018
Roche experimental flu drug clears second Phase 3
July 17, 2018
Cassiopea prospects fill in as hair loss drug shows promise
July 16, 2018
Novartis' contacts with Trump lawyer broader than company let on, US senators charge
July 13, 2018
Novartis partners with French CDMO to bolster CAR-T supply
July 12, 2018
Dermavant finds 'cornerstone' drug in GSK's pipeline
July 12, 2018
Pfizer price hikes on pause after Trump pressure
July 11, 2018
Aquinox cuts staff by 50% in wake of late-stage miss
July 10, 2018
CTI cancer drug faces clouded future after study failure
July 9, 2018
Biogen Alzheimer's drug shows unexpected signs of promise
July 6, 2018
Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says
July 5, 2018
Catalent expands with $133M deal for Juniper
July 3, 2018
Sanofi expands China presence with new R&D hub
July 2, 2018
Tecentriq extends streak with win in breast cancer trial
July 2, 2018
Galapagos posts 'underwhelming' cystic fibrosis results, boosting Vertex
June 29, 2018
Biogen pays $700M to up stake in Samsung Bioepis
June 29, 2018
Akebia, Keryx to merge, creating $1B kidney disease company
June 28, 2018
Gottlieb calls out Perrigo for missed postmarket study deadline
June 27, 2018
Global Blood bets sickle cell drug success will convince FDA
June 27, 2018
FDA to pub surrogate endpoints used in cancer drug approvals
June 26, 2018
Jardiance shows potential in type 1 diabetes, clearing Phase 3 tests
June 26, 2018
Immunotherapy advances spur new look at cancer vaccines
June 25, 2018
Roche aims for first-mover edge in small cell lung cancer
June 25, 2018
Novo's case for oral semaglutide bolstered by Phase 3 trial wins
June 21, 2018
Purdue Pharma lays off 350, cutting remainder of sales force
June 20, 2018
Anika shares slump on Phase 3 miss
June 20, 2018
Roche buys out Foundation Med in $2.4B bet on targeted cancer treatment
June 19, 2018
Solid finds its footing as FDA lifts trial hold
June 18, 2018
Valeant hit with CRL for key dermatology drug
June 18, 2018
Bluebird's changes to LentiGlobin begin to pay off
June 15, 2018
Recipharm to pay $60M for Sanofi manufacturing plant
June 14, 2018
Sage licenses out depression drug in Asia, adding to cash warchest
June 14, 2018
Biosimilars could still pack revenue-busting punch, analyst suggests
June 13, 2018
FDA permits more expansive communication between drugmakers, payers
June 13, 2018
Sun Pharma gets reprieve as FDA clears key Halol plant
June 12, 2018
Allergan notches another CGRP success, but faces changing migraine market
June 11, 2018
AbbVie, Roche win key US approval for blood cancer drug
June 11, 2018
Sanofi partners with Translate Bio on mRNA vaccines
June 11, 2018
Novartis won't face Swiss criminal probe over payments to Trump lawyer
June 7, 2018
ASCO18: 3 unanswered questions from oncology's largest conference
June 6, 2018
ASCO18: Who were the big winners and losers?
June 6, 2018
ASCO18: Bristol-Myers fights for its place in first-line lung cancer
June 5, 2018
ASCO18: Celgene makes its case as CAR-T rival in lymphoma
June 3, 2018
ASCO18: Merck raises the bar in lung cancer with Keytruda data
June 3, 2018
ASCO18: Bristol-Myers, Nektar forge ahead with Phase 3 tests for cancer combo
June 2, 2018
ASCO18: Positive readout marks step forward for Bluebird's CAR-T
June 1, 2018
Gilead's filgotinib clears mid-stage test in arthritis
May 31, 2018
PhRMA criticizes ICER in latest skirmish over valuing drugs
May 31, 2018
Allergan to sell off women's health, anti-infective businesses
May 30, 2018
AstraZeneca won't submit lung drug for COPD after 2nd study miss
May 30, 2018
Tecentriq trial wins boost Roche bid to compete with Merck
May 29, 2018
AstraZeneca's Imfinzi delivers survival benefit in Stage 3 lung cancer
May 25, 2018
Cancer drug spending climbs, with top winners earning lion's share
May 24, 2018
Momentum grows for hemophilia gene therapies
May 22, 2018
Regeneron's Aris Baras on probing the genome to find drugs for NASH
May 21, 2018
Pharma turn to NASH unlikely to mirror meteoric rise of hep C
May 21, 2018
FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq
May 21, 2018
Celgene, J&J top complaint list to FDA for blocking generics
May 18, 2018
5 takeaways from the first look at cancer's biggest conference
May 17, 2018
To shame drugmakers, CMS publicizes price hikes
May 16, 2018
Top Novartis lawyer to exit over deal with Trump insider
May 16, 2018
Gilead finds new home in Europe for CAR-T manufacturing
May 15, 2018
Bluebird widens hunt for TCR therapies in revised Medigene deal
May 14, 2018
AstraZeneca lung drug comes up short in COPD
May 11, 2018
Tecentriq stumbles in Phase 3 colon cancer study
May 10, 2018
Walmart to limit opioid prescriptions to 7-day supply
May 9, 2018
Novartis paid $1.2M to firm linked to Trump attorney
May 9, 2018
Takeda secures Shire takeover with $62B deal
May 8, 2018
J&J's ketamine-based antidepressant sees mixed results in Phase 3
May 7, 2018
Merck bets Moderna's mRNA tech can unlock KRAS puzzle
May 5, 2018
FDA approves Andexxa in major boost to Portola
May 4, 2018
Fremanezumab approval by mid-June unlikely, Teva says
May 3, 2018
Regeneron, Sanofi drop PCSK9 price in deal with Express Scripts
May 2, 2018
IDO drug development scaled back in wake of Incyte trial miss
May 2, 2018
Merck, riding clinical success, eyes cancer immunotherapy lead
May 1, 2018
Q1 earnings preview: Novo, Celgene still to come
May 1, 2018
Saunders: All options remain on the table for Allergan
April 30, 2018
Opdivo sales rise again, but analysts question what's next
April 26, 2018
Ocrevus fuels fast start to year for Roche
April 26, 2018
Biogen to increase stake in biosimilar developer Samsung Bioepis
April 25, 2018
GSK new drug success eclipsed by currency, Advair slump
April 25, 2018
Immunotherapies, biosimilars to dominate next week of earnings
April 24, 2018
Setback for AstraZeneca cancer combo raises MYSTIC stakes
April 24, 2018
Lilly raises sales forecasts as diabetes drugs outperform
April 24, 2018
As India, China drug industries mature, FDA scrutiny an overhang
April 23, 2018
Top challenges facing drug supply chains
April 23, 2018
Pfizer's Herceptin copy hits FDA roadblock
April 23, 2018
Biogen, facing questions, turns again to Ionis in $1B research deal
April 20, 2018
Astellas sells Agensys facilities to Gilead
April 19, 2018
Cosentyx jitters weigh on Novartis
April 19, 2018
Pushing 'value,' Harvard Pilgrim tests outcomes deals
April 18, 2018
DEA seeks to more strictly manage opioid manufacturing
April 18, 2018
Sanofi nears deal to sell EU generics unit for $2.4B
April 17, 2018
Two years after cancer setback, Bristol-Myers' new biomarker bet pays off
April 16, 2018
I/O combos inch forward in pharma's lung cancer quest
April 16, 2018
Q1 kicks off with J&J, Novartis, Glaxo results
April 13, 2018
Lonza makes gene therapy ambitions clear with Texas plant
April 12, 2018
GSK offloads gene therapy drugs to UK's Orchard
April 12, 2018
CVS hands pharmacists tool to compare drug prices
April 11, 2018
Pfizer's Inlyta misses mark in Phase 3 kidney cancer study
April 11, 2018
With study success, AbbVie's arthritis hopeful looks to be a safer bet
April 9, 2018
Novartis buys AveXis for $8.7B, broadening gene therapy bet
April 9, 2018
AbbVie staves off another biosimilar challenge to Humira
April 6, 2018
Incyte cancer study fails, setting back drug combo hopes
April 6, 2018
Corning to build NC facility in pharma packaging expansion
April 5, 2018
Boehringer joins checkpoint inhibitor race with OSE deal
April 5, 2018
Alnylam taps Agilent for commercial API supply
April 4, 2018
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
April 4, 2018
Proposed China tariffs target dozens of medical products
April 4, 2018
Rigel's fostamatinib falls short in Phase 2
April 3, 2018
Pfizer surprises ATTR rivals with tafamidis success
April 2, 2018
Eisai partners with Nichi-Iko in generics pact
March 29, 2018
Indivior inks deal for preclinical addiction treatment candidate
March 29, 2018
PhRMA goes after drug 'middlemen' in new ad attack
March 28, 2018
Roche reports deaths of patients taking Hemlibra
March 28, 2018
GSK buys Novartis stake in consumer business for $13B
March 27, 2018
Lilly's bet on pain stands out amid bare pharma pipeline
March 26, 2018
Roche's momentum grows as Tecentriq combo delivers survival benefit
March 26, 2018
GSK drops bid to acquire Pfizer's consumer business
March 23, 2018
Novartis readies MS drug for speedy US filing
March 22, 2018
FDA warns Indian drugmaker over open-air API production
March 22, 2018
Regeneron, Alnylam partner to turn discovery into new drugs for NASH
March 22, 2018
Seattle Genetics secures key label expansion for Adcetris
March 21, 2018
Tecentriq combo success boosts Roche in lung cancer
March 20, 2018
Heron's non-opioid pain drug succeeds in Phase 3, lifting shares
March 19, 2018
Ionis taps majority-owned Akcea to launch inotersen
March 16, 2018
Novartis splits operations unit as part of leadership reshuffle
March 15, 2018
SEC charges against Theranos, Holmes dispel last shreds of unicorn myth
March 15, 2018
Federal panel calls for 'urgent action' on cancer drug prices
March 14, 2018
Incyte study could bring lessons for cancer immunotherapy
March 14, 2018
Teva hands back rights to preclinical CGRP blocker
March 13, 2018
AstraZeneca pushes back readout of key lung cancer study
March 12, 2018
Regeneron-Sanofi cholesterol drug cuts heart risk in major study
March 10, 2018
Despite crowded I/O field, pharma, VCs still eager to invest
March 9, 2018
FDA recognizes GMP inspections by 4 more EU states
March 8, 2018
Merck partners with Eisai in sweeping bet on Keytruda combo
March 8, 2018
UnitedHealthcare to use rebates to lower drug costs for patients
March 6, 2018
Santhera shares slide as Raxone fails in MS study
March 5, 2018
Dermira acne drug misses the mark, surprising investors
March 5, 2018
Roche, Ionis showcase potential of Huntington's disease drug
March 2, 2018
Regeneron links rise in Eylea safety reports to syringes
March 1, 2018
Mylan partners with Revance to develop a Botox biosimilar
March 1, 2018
Benzo overprescribing risk may be overlooked amid opioid crisis
Feb. 28, 2018
AstraZeneca spins out new biotech, shedding autoimmune drugs
Feb. 28, 2018
Lilly wins broader Verzenio approval, drawing even with rivals
Feb. 27, 2018
Messy Phase 2 data for Arca's heart drug leave investors unimpressed
Feb. 26, 2018
Cancer and the microbiome: What's old is new again
Feb. 26, 2018
Patent board ruling undermines Allergan effort to defend Restasis patents
Feb. 26, 2018
Bellicum outlines path to restart US studies of cell therapy
Feb. 23, 2018
CAR-T growing up with big pharma's big bet
Feb. 20, 2018
Charles River boosts CRO chops with $800M deal for MPI
Feb. 15, 2018
Biogen shares fall after unexpected 'variability' in Alzheimer's studies
Feb. 15, 2018
Bristol-Myers bets $1.85B on combo potential of Nektar cancer drug
Feb. 14, 2018
Teva's Copaxone sales hit hastened with OK of Novartis copy
Feb. 13, 2018
Maker of Oxycontin to halt opioid promotion to doctors
Feb. 12, 2018
Boehringer ends Alzheimer's research for PDE9 blocker
Feb. 9, 2018
FDA warning letter details violations at Celltrion plant
Feb. 8, 2018
Citing lower tax rate, Amgen plans new biomanufacturing plant
Feb. 8, 2018
FDA knocks back Novartis' Advair copy
Feb. 8, 2018
Express Scripts: Plan drug spending rose at slowest rate in 24 years
Feb. 7, 2018
Mixed results muddy Sanofi's plans for 2018 growth
Feb. 7, 2018
Gilead forecasts steep slide in 2018 hepatitis C revenues
Feb. 6, 2018
Strong data lift profile of J&J's cancer drug apalutamide
Feb. 5, 2018
Biopharma in charts: Key takeaways from Q4 earnings
Feb. 5, 2018
Keytruda boosts Merck, yet 2018 will be crucial year
Feb. 2, 2018
Celltrion biosimilars plant hit with FDA warning letter
Feb. 1, 2018
Pharma tees up US capital spending, yet details remain vague
Feb. 1, 2018
FDA adds black box warning to Intercept's Ocaliva
Feb. 1, 2018
Aegerion sentenced for mismarketing of cholesterol drug
Jan. 31, 2018
Boosted by tax reform, Lilly looking for ways to spend $9B
Jan. 31, 2018
How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
Jan. 29, 2018
5 Drivers spurring use of real-world evidence
Jan. 29, 2018
Aradigm stung by FDA rejection of inhaled antibiotic
Jan. 29, 2018
AbbVie shares boom on rosy outlook
Jan. 26, 2018
Chinese drugmakers tap GE tech, seeing biologic boom ahead
Jan. 25, 2018
Spark deals Novartis ex-US rights to gene therapy for $105M
Jan. 25, 2018
US in 'desperate need' of biosimilars: Novartis' Narasimhan
Jan. 24, 2018
Novartis pulls Arzerra outside US markets amid rising CLL competition
Jan. 24, 2018
Novartis predicts growth pick-up on back of Cosentyx, Entresto
Jan. 24, 2018
Astellas, Vical's CMV vaccine comes up short in Phase 3
Jan. 23, 2018
Celgene buys Juno for $9B, deepening bet on CAR-T
Jan. 22, 2018
FDA to speed public notification of product recalls
Jan. 19, 2018
Ipca Labs buys North Carolina manufacturer for $9.7M
Jan. 18, 2018
With eye to Brexit, Almac to invest $42M in Ireland site
Jan. 18, 2018
Patent setback could sting J&J prostate cancer franchise
Jan. 18, 2018
Exelixis details Phase 3 cabozantinib results
Jan. 17, 2018
Price for Spark gene therapy too high, ICER says
Jan. 16, 2018
BioPharma Dive's 3 predictions for 2018 and beyond
Jan. 12, 2018
Closing JPM18: Winners and losers, brighter days for neuroscience
Jan. 11, 2018
JPM18 Day 3: Valeant and Acorda make plans, promises of M&A
Jan. 10, 2018
Price competition to hit oncology next: BioPharma Dive's 2018 predictions
Jan. 10, 2018
JPM18: Bluebird set to file 3 drugs for approval by 2019
Jan. 9, 2018
JPM18 Day 2: Roche on gene therapy, Aimmune nears key readout and outpatient CAR-T
Jan. 9, 2018
JPM18 Day 1: Celgene bullish, Alnylam tempers hopes, Axovant shocks
Jan. 8, 2018
Celgene aims to quell growth worries with $7B Impact deal
Jan. 7, 2018
Pfizer pulls back from neuroscience, ending research
Jan. 7, 2018
FDA rejects Allergan's latest bid to block Restasis copies
Jan. 5, 2018
FDA aims to strengthen oversight of compounded drug manufacturing
Jan. 4, 2018
MacroGenics finds new pharma partner in Roche
Jan. 4, 2018
Drug approvals surged in 2017. What does that mean for pharma?
Jan. 3, 2018
Allergan to cut 1,000 jobs as generic competition threatens
Jan. 3, 2018
Pfizer teams up with Sangamo to develop ALS gene therapy
Jan. 3, 2018
J&J builds case for ketamine-based depression drug
Jan. 2, 2018
Mallinckrodt builds pipeline through $1.2B Sucampo deal
Dec. 26, 2017
J&J enters CAR-T field with $350M Legend deal
Dec. 22, 2017
Biopharma trends to watch in 2018
Dec. 22, 2017
Kymriah, Yescarta could be cost-effective, ICER finds
Dec. 21, 2017
Juno inks CAR-T supply deal with Thermo Fisher
Dec. 21, 2017
Galera scores trial win for cancer side effect treatment
Dec. 20, 2017
FDA approves Spark blindness drug in gene therapy first
Dec. 19, 2017
Aerie eyes glaucoma market after early FDA win
Dec. 19, 2017
Novartis buys regulatory fast pass for $130M
Dec. 18, 2017
Trial miss sets back Merck's Keytruda plans in stomach cancer
Dec. 15, 2017
EMA signs off on Samsung BioLogics manufacturing plant
Dec. 14, 2017
FDA warns Korean OTC manufacturer for GMP violations
Dec. 14, 2017
Regeneron's play for a stake in the I/O market boosted by study success
Dec. 14, 2017
ASH 2017: What you missed
Dec. 13, 2017
ASH17: J&J's Darzalex delivers combo win
Dec. 12, 2017
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
Dec. 11, 2017
Shire CEO: Hemophilia will remain a core business
Dec. 10, 2017
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
Dec. 10, 2017
ASH17: Seattle Genetics sees market opportunity in cancer combo success
Dec. 10, 2017
ASH17: bluebird bio makes strides in CAR-T, gene therapy
Dec. 9, 2017
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
Dec. 9, 2017
Gilead deepens CAR-T push with deal for Cell Design
Dec. 7, 2017
Chasing leaders, Juno rides CAR-T momentum into ASH
Dec. 7, 2017
Wuxi preps for biologics manufacturing surge in China
Dec. 7, 2017
Roche's Tecentriq combo cuts risk of lung cancer progression
Dec. 7, 2017
Biogen inks outcomes-based contract for MS meds
Dec. 6, 2017
FDA cautiously lifts holds on combo studies of checkpoint inhibitors
Dec. 6, 2017
Updated: Sanofi discontinues C. diff candidate in blow to vaccine unit
Dec. 4, 2017
7 Biopharmas to watch at ASH 2017
Dec. 4, 2017
Mylan wins first US approval of Herceptin biosimilar
Dec. 4, 2017
Deal of the Year: Gilead Buys Kite Pharma
Dec. 4, 2017
Most Impressive Drug Launch: Roche's Ocrevus
Dec. 4, 2017
The BioPharma Dive Awards for 2017
Dec. 4, 2017
Bayer unblinds cancer drug study early to investigate patient deaths
Dec. 1, 2017
Corning adds 185 jobs to support pharma packaging production
Nov. 30, 2017
Sanofi to propose limits on use of dengue vaccine after safety signal
Nov. 30, 2017
FDA knocks generic maker for misbranding sleep aid
Nov. 29, 2017
Biopharma in charts: New drugs and the search for growth
Nov. 28, 2017
Pfizer, Merck KGaA's Bavencio falls short in gastric cancer study
Nov. 28, 2017
AstraZeneca launches JV, furthering play for China market
Nov. 27, 2017
Teva restructures to stabilize struggling business
Nov. 27, 2017
J&J eyes broader market for blood cancer med Darzalex
Nov. 22, 2017
GSK boosted by US approval of two-drug HIV pill
Nov. 22, 2017
Cytokinetics to discontinue ALS drug after Phase 3 miss
Nov. 21, 2017
Roche lung cancer results boost Tecentriq versus I/O rivals
Nov. 20, 2017
Proposed Medicare policy could shift drug rebates to consumers
Nov. 17, 2017
Recipharm to shutter two plants, cutting 225 jobs
Nov. 16, 2017
Avista doubles API manufacturing capacity at CO facility
Nov. 16, 2017
Quotient Sciences buys UK CDMO in third acquisition of year
Nov. 16, 2017
Janssen picks up second GI drug from Ionis
Nov. 16, 2017
Novartis sets Cosentyx hopes higher
Nov. 15, 2017
AstraZeneca wins US approval for asthma biologic
Nov. 15, 2017
Loxo parlays cancer drug success into $1.5B deal with Bayer
Nov. 14, 2017
Novartis turns to startup to boost gene editing efforts
Nov. 13, 2017
Zymeworks adds 6th pharma partner with J&J deal
Nov. 13, 2017
Juno analysis of shuttered study offers clues for CAR-T
Nov. 10, 2017
Sage shares boom on success of postpartum depression drug
Nov. 9, 2017
'Hard' Brexit risks disrupting supply of thousands of drugs
Nov. 8, 2017
Roche to shift packaging operations, trimming 235 jobs
Nov. 8, 2017
Spark gene therapy for blindness could come at steep cost
Nov. 8, 2017
Regeneron boosted by Eylea strength
Nov. 8, 2017
FDA lifts clinical hold on Cellectis CAR-T
Nov. 7, 2017
FDA agrees to review TherapeuticsMD drug, dropping safety demands
Nov. 6, 2017
One-two punch hits Teva, sparking worries about debt
Nov. 3, 2017
FDA to recognize GMP inspections by 8 EU drug regulators
Nov. 2, 2017
Diabetes drags on Sanofi, even as Dupixent shines
Nov. 2, 2017
ICER looks to expand watchdog role with new funding
Nov. 1, 2017
AstraZeneca secures US approval for 'cornerstone' cancer drug
Nov. 1, 2017
Bluebird marks progress on Lentiglobin gene therapy
Nov. 1, 2017
AstraZeneca looks to build edge in early-stage lung cancer
Oct. 31, 2017
Pharma's betting big on China, but R&D boom still to come
Oct. 30, 2017
Novartis bolsters oncology with $3.9B Advanced Accelerator buy
Oct. 30, 2017
Merck sales slip, even as Keytruda gains ground
Oct. 27, 2017
What to expect from the rest of pharma's earnings
Oct. 26, 2017
Gilead warns hep C sales could fall further
Oct. 26, 2017
Drug production in Puerto Rico still disrupted, FDA says
Oct. 26, 2017
Lilly to spend $72M on upgrading insulin production
Oct. 26, 2017
Vertex grows CF franchise as combos move forward
Oct. 26, 2017
With Advair copies looming, GSK keeps focus on new drugs
Oct. 25, 2017
Eyes on Alcon as Novartis notches modest growth
Oct. 24, 2017
Vaccine approval buoys GSK new drug push
Oct. 23, 2017
What's next for biopharma Q3 earnings
Oct. 20, 2017
Gritstone taps Arbutus' LNP tech for RNA-based therapies
Oct. 19, 2017
J&J says Puerto Rico plants returning to full operations
Oct. 19, 2017
Gilead wins US approval for CAR-T cancer therapy
Oct. 18, 2017
Despite increased spending, orphan drugs still small piece of US medicines market
Oct. 18, 2017
In Congressional spotlight, drug industry groups blame each other
Oct. 18, 2017
Amneal, Impax combine amid generics crunch
Oct. 17, 2017
Federal judge invalidates Restasis patents in blow to Allergan
Oct. 16, 2017
Exelixis continues to gain momentum with positive data
Oct. 16, 2017
What Q3 earnings will look like for 5 pharma giants
Oct. 13, 2017
Spark's gene therapy for blindness takes major step toward approval
Oct. 12, 2017
Pfizer sells off Colorado facility to CordenPharma
Oct. 12, 2017
Sanofi commits €170M to expand flu vaccines production
Oct. 12, 2017
Long rundowns of side effects can make drugs seem less risky, study finds
Oct. 11, 2017
Lupin expands US presence with $150M Symbiomix deal
Oct. 11, 2017
Lilly's plans for abemaciclib dented by lung trial miss
Oct. 10, 2017
Flexion secures US approval for osteoarthritis drug
Oct. 9, 2017
Strong data for Pompe therapy boosts Amicus
Oct. 3, 2017
Rigel blood drug hits mark in mid-stage study
Oct. 3, 2017
Express Scripts: Specialty meds driving up US drug spend
Oct. 2, 2017
Arbutus boosted by $116M investment from Roivant
Oct. 2, 2017
Zogenix looks to filing after epilepsy trial success
Sept. 29, 2017
A drug 15 years in the making: Alnylam's quest to prove RNAi
Sept. 29, 2017
Abeona taps Brammer Bio for gene therapy manufacturing support
Sept. 28, 2017
AbbVie to keep limits on price hikes next year, denying backtrack
Sept. 27, 2017
Axovant's closely watched Alzheimer's drug fails late-stage trial
Sept. 26, 2017
Without power, Puerto Rico's drug manufacturing left battered by Maria
Sept. 25, 2017
Premium price for Novartis' CAR-T sparks pushback from top PBM
Sept. 25, 2017
Versartis crashes after Phase 3 miss
Sept. 22, 2017
Brammer Bio doubles manufacturing capacity at Florida site
Sept. 21, 2017
Provention builds pipeline with Janssen licensing deal
Sept. 21, 2017
Alnylam soars on trial win for RNAi drug
Sept. 20, 2017
Bayer ends sales of Essure implant outside of US
Sept. 19, 2017
GSK's respiratory business boosted by lung drug approval
Sept. 19, 2017
AbbVie, Roche to seek broader market for leukemia drug after trial success
Sept. 18, 2017
Smaller sales forces get the job done in rare disease
Sept. 18, 2017
Nabriva shares leap higher on antibiotic trial success
Sept. 18, 2017
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
Sept. 15, 2017
Amgen, Allergan win first approval of cancer biosimilar in US
Sept. 14, 2017
FDA calls for industry input on continuous manufacturing guidelines
Sept. 14, 2017
Pfizer, Astellas eye wider market for prostate cancer drug
Sept. 14, 2017
Amicus drops wound drug after trial miss
Sept. 13, 2017
ICER analysis latest salvo in debate over Repatha price
Sept. 12, 2017
Sage stock sinks after epilepsy drug fails to beat placebo
Sept. 12, 2017
Blockbuster hopeful Dupixent succeeds in asthma study
Sept. 11, 2017
ESMO: New momentum for AstraZeneca as lung cancer studies impress
Sept. 11, 2017
ESMO: Lilly breast cancer drug keeps pace with Pfizer, Novartis rivals
Sept. 9, 2017
ESMO: Foundation biomarker test could help boost immunotherapy
Sept. 8, 2017
Opdivo combo shows early survival benefit in kidney cancer
Sept. 7, 2017
Cell therapy emergence opens up new markets for shippers, logistic companies
Sept. 7, 2017
AstraZeneca sees first-in-class potential for asthma biologic
Sept. 7, 2017
FDA warns drugmaker over misleading marketing of opioid
Sept. 6, 2017
Verastem bet on blood cancer drug pays off with trial success
Sept. 6, 2017
Industry Pulse: 10 charts on M&A, I/O and biosimilar threats
Sept. 1, 2017
Janssen drops MacroGenics cancer candidate over safety concerns
Sept. 1, 2017
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
Aug. 31, 2017
Incyte, Merck build case for skin cancer combo
Aug. 31, 2017
In historic first, FDA approves Novartis CAR-T therapy
Aug. 30, 2017
Lilly speeds up timeline for refiling of baricitinib
Aug. 30, 2017
AstraZeneca strikes $400M deal with Takeda for Parkinson's drug
Aug. 29, 2017
Bristol-Myers, Pfizer continue to build case for Eliquis
Aug. 28, 2017
Novartis rare disease drug opens up new way to treat heart disease
Aug. 27, 2017
Regenxbio picks up Dimension in $86M stock deal
Aug. 25, 2017
Samsung Bioepis locks down EU approval for Humira biosimilar
Aug. 24, 2017
FDA warns compounding pharmacy of wood contamination
Aug. 24, 2017
Roche lines up February decision date for hemophilia prospect
Aug. 24, 2017
Pfizer secures patent in India for pneumonia vaccine
Aug. 23, 2017
In cost debate, Amgen stands by Repatha's value
Aug. 23, 2017
PCSK9 inhibitors still too pricey, study finds
Aug. 22, 2017
Ironwood wins FDA approval for combo gout drug
Aug. 21, 2017
Samsung Bioepis partners with Takeda to break into novel biologics
Aug. 21, 2017
Expanded label boosts AstraZeneca and Merck's Lynparza
Aug. 18, 2017
House Democrats to probe 'skyrocketing' prices for MS meds
Aug. 17, 2017
Valeant says FDA to reclassify troubled Tampa plant
Aug. 17, 2017
CEOs break with Trump amid disintegration of business councils
Aug. 17, 2017
Bristol-Myers' Opdivo comes up short in kidney cancer study
Aug. 16, 2017
Amid CEO exits, J&J chief to stay on Trump manufacturing council
Aug. 15, 2017
Mundipharma picks up chemo prodrug in $250M deal
Aug. 15, 2017
As federal efforts slow, states take up drug pricing pushback
Aug. 14, 2017
Merck CEO resigns from Trump's manufacturing council
Aug. 14, 2017
PharmaTech liquid drugs possibly contaminated, FDA says
Aug. 10, 2017
Manufacturing issues threaten delay for Aerie eye drug
Aug. 10, 2017
Alnylam review turns up no clear answers on revusiran deaths
Aug. 10, 2017
Mylan cuts sales forecast as pricing pressure grows
Aug. 9, 2017
Roche sells off dermatitis drug to Dermira
Aug. 8, 2017
Lilly's turn to pain gathers momentum
Aug. 7, 2017
Payer coverage boosts Radius' Tymlos
Aug. 4, 2017
J&J set back by negative panel vote for sirukumab
Aug. 3, 2017
Cytokinetics inches forward with heart failure program
Aug. 2, 2017
Vertex wins new Kalydeco approval, ups sales forecast
Aug. 1, 2017
Express Scripts shuts out 64 branded drugs from 2018 formulary
July 31, 2017
Unfazed by competition, Allergan sees room at CGRP table
July 28, 2017
AbbVie confident in strategy as Humira mints money
July 28, 2017
GSK looks to exit rare diseases
July 27, 2017
Novartis taps Cryoport for CAR-T logistics support
July 27, 2017
Corning invests $500M to build better glass packaging for pharma
July 27, 2017
MYSTIC flop a major blow to AstraZeneca's I/O hopes
July 27, 2017
Merck undercuts Pfizer on Remicade biosimilar price
July 26, 2017
GSK overhauls R&D, axes 30 programs to regain edge
July 26, 2017
Lilly maps out new approach to cancer R&D
July 25, 2017
Nektar secures $400M deal with Lilly for Phase 1 drug
July 24, 2017
5 trends shaping Alzheimer's drug development
July 17, 2017
Amid supply shortage, FDA clears import of in-demand drug
July 13, 2017
Lilly extends patent runway for Cialis
July 13, 2017
FDA panel unanimously backs approval of Novartis CAR-T
July 12, 2017
FDA changes tune on Amicus Fabry disease drug
July 11, 2017
Safety issues for Novartis CAR-T therapy main focus of FDA
July 10, 2017
Generic drug association sues to stop state price-gouging law
July 7, 2017
Novo Nordisk recalls six batches of insulin cartridge holders
July 6, 2017
3 Keytruda studies put on clinical hold after deaths
July 6, 2017
Industry paid $8.2B to docs, hospitals last year
July 5, 2017
Daiichi Sankyo pulls plug on Coherus biosimilar
July 5, 2017
A head above the rest? Drugmakers face off in migraine market
June 30, 2017
Patheon maps out $45M investment in services network
June 29, 2017
Chemicals giant BASF builds out ibuprofen API production
June 29, 2017
Exelixis clears debt, turning eye to future growth
June 29, 2017
SEC charges ex-Ariad employees with insider trading
June 28, 2017
Alder scores CGRP win but investors not impressed
June 27, 2017
Alnylam lines up Phase 3 for another RNAi drug
June 26, 2017
Seattle Genetics' Adcetris succeeds in study but shares slide
June 26, 2017
CHMP decisions: Novartis locks up backing for Kisqali
June 23, 2017
Mylan board weathers shareholder challenge
June 23, 2017
FDA surprises with rejection of Pfizer's Epogen biosimilar
June 23, 2017
Takeda set to open new German manufacturing facilities
June 22, 2017
FDA targets regulatory 'gaming' to boost generic competition
June 21, 2017
Report: Biopharma dealmaking set to level off
June 21, 2017
FDA approves new antibiotic for skin infections
June 20, 2017
Clovis soars on strong results for PARP inhibitor
June 19, 2017
BioMarin secures FDA approval for Ireland production facility
June 15, 2017
Sanofi continues biologics push, building on recent approvals
June 15, 2017
Novartis, Verily back new $300M fund for European biotechs
June 15, 2017
Rebates not to blame for rising drug costs, says PBM trade group
June 14, 2017
How Merck hopes to win in I/O combos: Q&A with Roy Baynes
June 14, 2017
Supreme Court ruling gives biosimilar makers a boost
June 13, 2017
Gene therapy by the numbers
June 12, 2017
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
June 12, 2017
Novartis' CAR-T stacks up to Kite in lymphoma
June 7, 2017
ASCO17: CAR-Ts steal the show
June 6, 2017
ASCO17: Juno marks progress with second-gen CAR-T
June 5, 2017
ASCO 2017: What you missed
June 5, 2017
ASCO17: Roche's Perjeta cuts risk in Aphinity, but is it enough?
June 5, 2017
ASCO17: Roche's Alecensa bests Xalkori in lung study
June 5, 2017
ASCO17: AstraZeneca's Lynparza stays step ahead of PARP rivals
June 4, 2017
ASCO17: Incyte pads its IDO numbers
June 3, 2017
ASCO17: Loxo shows promise of biomarker approach to cancer
June 3, 2017
FDA cites Braun Medical for repeat GMP violations
June 1, 2017
Chiltern acquires Japanese CRO in Asia expansion bid
June 1, 2017
US may have overpaid $1.3B for Mylan's EpiPen, HHS watchdog says
June 1, 2017
Drug rebates may shift costs to Medicare, study finds
May 31, 2017
AstraZeneca taps outcomes deals to boost CV, diabetes meds
May 31, 2017
Gilead tees up filing for HIV triple combo after Phase 3 wins
May 30, 2017
Industry Pulse: R&D spending in charts
May 30, 2017
Industry Pulse: Aging blockbusters tax bottom lines
May 26, 2017
Problems at Sun Pharma plant trip up drug approval
May 25, 2017
J&J settles OTC manufacturing issue for $33M
May 25, 2017
Aerie shares rise on trial success for eye drug
May 25, 2017
Under new CEO, Alexion continues overhaul of leadership
May 24, 2017
Trial success buoys AstraZeneca's hopes for asthma biologic
May 23, 2017
Overcoming delay, Sanofi, Regeneron win US approval for RA drug
May 23, 2017
Celgene MS drug succeeds in second Phase 3 study
May 22, 2017
Safety signal derails expected approval of Amgen bone drug
May 22, 2017
Thermo Fisher to buy Patheon in $7.2B deal, accelerating CDMO consolidation
May 18, 2017
7 Areas to watch from the ASCO abstracts
May 18, 2017
FDA warns of higher amputation risk for J&J's Invokana
May 17, 2017
Coherus wins Humira patent ruling, chipping away at AbbVie's defenses
May 17, 2017
Taking office, Gottlieb keeps drug pricing front and center
May 16, 2017
EU investigating generic drugmaker over cancer drug price hikes
May 15, 2017
Can value-based deals work if patients don't take the drug?
May 15, 2017
AstraZeneca rises after positive lung cancer results for key drug
May 12, 2017
Indian drugmaker stages worker strike to avoid FDA inspection
May 11, 2017
Second Advair copy rejected, giving GSK short-term respite
May 11, 2017
Merck bolsters I/O edge with Keytruda combo approval
May 11, 2017
Senate confirms Scott Gottlieb as FDA chief
May 10, 2017
PhRMA ousts 22 drugmakers from ranks in membership change
May 10, 2017
Valeant pitches a turnaround but new roadblocks complicate story
May 9, 2017
Kite discloses patient death in CAR-T trial, sparking safety worries
May 8, 2017
Pfizer making progress on Hospira manufacturing issues, execs say
May 4, 2017
BIO accuses insurer report of shifting blame on drug prices
May 4, 2017
Weak Xtandi sales spur questions on Pfizer's $14B Medivation takeover
May 3, 2017
Pieris teams up with AstraZeneca on respiratory drug development
May 3, 2017
Amgen inks first money-back guarantee for Repatha
May 2, 2017
Merck sees Keytruda gains, offsetting generic hits to sales
May 2, 2017
Q1 Earnings Preview: Gilead, Merck, Pfizer, Allergan
May 1, 2017
Radius targets quick ramp up for newly approved osteoporosis drug
April 30, 2017
Diabetes decline hangs over Sanofi's growth in specialty care, immunology
April 28, 2017
Sun Pharma tripped up by Form 483 at Dadra unit
April 27, 2017
Daiichi Sankyo to invest $135M in ADC manufacturing expansion
April 27, 2017
Amid sales growth, Roche plans defense from biosimilar threats
April 27, 2017
Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi
April 26, 2017
Medicines Co. charts ambitious late-stage tests for heart drug
April 26, 2017
FDA busts 14 companies for selling bogus cancer cures
April 25, 2017
Lilly gets lift from new drugs, but baricitinib setback hangs over revenue growth
April 25, 2017
Cancer immunotherapy works, but how to find which patients will benefit?
April 25, 2017
Biogen, BioMarin secure orphan drug endorsements in Europe
April 24, 2017
Q1 Earnings Preview: Novartis, Lilly, Biogen, GSK, Amgen
April 24, 2017
Biopharma opening up to new ways of partnering on R&D
April 20, 2017
Theranos pays $4.65M to refund cost of blood tests in Arizona
April 19, 2017
Former Dendreon CEO debuts new public company in reverse merger
April 19, 2017
Pharma bellwether J&J not worried about drug pricing for specialty meds
April 18, 2017
Bristol-Myers taps Danish biotech in NASH biomarker deal
April 17, 2017
GE acquires British cold chain specialist, deepening cell therapy push
April 13, 2017
FDA warns Teva over violations at China plant
April 13, 2017
University of California appeals patent setback, extending CRISPR fight
April 13, 2017
Biotech calls on 'Poop Troop' to drive constipation awareness
April 12, 2017
SV Health secures $400M for new life sciences venture fund
April 12, 2017
Cancer combos key to AstraZeneca success, but rivals have long lead
April 11, 2017
In familiar routine, ICER finds rheumatoid arthritis drugs overpriced
April 10, 2017
5 trends shaping rare disease drug development
April 10, 2017
FDA shoots down Merck's bid to expand Januvia label
April 7, 2017
Indoco Remedies handed FDA warning letter
April 6, 2017
PhRMA takes shot at payers in drug pricing war
April 6, 2017
Scott Gottlieb commits to defend FDA's 'gold standard' for drug reviews
April 5, 2017
AACR recap: IDOs under the microscope
April 5, 2017
AACR: NewLink's IDO data shows promise, but is it enough?
April 4, 2017
AACR: Incyte hedges bet on combo strategy
April 3, 2017
AACR: Busy start for Bristol-Myers Squibb's Opdivo
April 3, 2017
CAR-T race heats up as Kite, Novartis complete filings to FDA
April 2, 2017
Warp Drive Bio teams up with GSK, taking aim at 'undruggable' targets
March 30, 2017
Agenus trims staff, narrows focus in restructuring
March 30, 2017
Drug prices continue to climb, but who's to blame?
March 30, 2017
GSK breathes sigh of relief as Mylan Advair copy rejected
March 29, 2017
Vertex boosted by strong trial data for next-gen CF drug
March 29, 2017
AACR preview: IDO1, CDK 4/6 and cancer combos
March 29, 2017
In twisting patent fight, CRISPR Therapeutics scores win in Europe
March 28, 2017
Alexion taps ex-Baxalta chief as new CEO
March 27, 2017
Lilly touts $850M manufacturing investment as CEO stumps for tax reform
March 24, 2017
Control over production data still tripping up foreign drug manufacturers with FDA
March 23, 2017
Valeant hopes for August approval of eye drug
March 23, 2017
J&J, GSK pull ads from YouTube amid display concerns
March 23, 2017
Biogen staves off patent challenge to blockbuster MS drug
March 22, 2017
Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin
March 20, 2017
Phase 3 win moves Lilly's breast cancer drug closer to market
March 20, 2017
Real world study shows cardiovascular benefit to SGLT2 drugs
March 20, 2017
Medicines Co. hits mark in ORION, plans PCSK9 Phase 3
March 17, 2017
Amgen's Repatha shows CV benefit, but falls short of expectations
March 17, 2017
FDA warns two manufacturers from China, India for GMP lapses
March 16, 2017
Takeda teams up with venture firm on drug discovery unit
March 16, 2017
Under fire, Marathon offloads Duchenne drug to PTC for $140M
March 16, 2017
AstraZeneca staves off Tesaro threat to PARP crown
March 14, 2017
Allergan taps CRISPR biotech Editas in eye care deal
March 14, 2017
Novartis locks up Kisqali approval, eyes Pfizer's lead
March 13, 2017
Mylan clears way for biosimilar Herceptin launch in US
March 13, 2017
Trump taps Scott Gottlieb to head FDA
March 10, 2017
Radius shares slide after FDA delays decision on bone drug
March 10, 2017
Nicox resubmits eye drug to FDA after manufacturing setback
March 9, 2017
Indian drugmaker slammed for repeated GMP failures
March 9, 2017
Trump 'enthusiastic' about drug price negotiation, lawmakers say
March 9, 2017
Despite hype, still much to uncover about immunotherapy
March 8, 2017
MS drugs too expensive, ICER says
March 7, 2017
Pressure builds on Marathon over orphan drug price
March 7, 2017
Changes to MYSTIC could set AstraZeneca up for success
March 6, 2017
Vertex fine tunes CF portfolio with Concert deal
March 6, 2017
Industry Pulse: Who's spending on R&D?
Feb. 28, 2017
Merck writes off $2.9B as new hep C reality blooms
Feb. 24, 2017
Pharma CEOs sign on to letter urging tax reform
Feb. 23, 2017
Safety concerns reemerge for Roche hemophilia drug
Feb. 23, 2017
Harvard Pilgrim bets on value-based drug payments with new deals
Feb. 22, 2017
Gilead snaps up Sarepta's priority review voucher for $125M
Feb. 21, 2017
FDA warns another Japanese drug manufacturer over GMP flaws
Feb. 16, 2017
Are commercial prospects limited for Valeant's Siliq?
Feb. 16, 2017
Broad Institute notches win in CRISPR patent battle
Feb. 15, 2017
Merck scraps late-stage study of Alzheimer's candidate
Feb. 15, 2017
Marathon presses pause on Emflaza launch after pricing pushback
Feb. 13, 2017
5 trends being impacted by biomarkers
Feb. 13, 2017
Liquid biopsies: The next frontier in cancer?
Feb. 13, 2017
Sanofi confident in case to overturn Praluent ban
Feb. 10, 2017
Regeneron, Sanofi win reprieve from court ban on Praluent
Feb. 9, 2017
Sanofi pins hopes on immunology as Lantus sales fade
Feb. 8, 2017
Teva CEO out, board chairman steps in as interim chief
Feb. 6, 2017
Innate's cancer immunotherapy falls short in Phase 2
Feb. 6, 2017
FDA warns Italian drug manufacturer for quality lapses
Feb. 2, 2017
Trump pushes pharma to boost drug production in US
Feb. 2, 2017
Pfizer counts on Ibrance as Prevnar sales slip
Jan. 31, 2017
Pfizer's Read sees positives for industry under Trump
Jan. 31, 2017
Insulin drugmakers sued for inflating prices
Jan. 31, 2017
Merck ups pricing transparency amid industry ad blitz
Jan. 30, 2017
Earnings Preview: Merck set to solidify I/O lead, Sanofi still looking for deals and more
Jan. 26, 2017
Intrexon picks up struggling GenVec to build delivery tech
Jan. 26, 2017
On the defensive, Bristol faces down I/O competition
Jan. 26, 2017
J&J seals $30B deal for Actelion
Jan. 26, 2017
Novartis aims to gain ground on I/O leaders
Jan. 25, 2017
As Trump moves to repeal, J&J says preserve some of ACA
Jan. 25, 2017
Anthem limits coverage for Biogen's new SMA drug
Jan. 24, 2017
J&J earnings disappoint, with no word on Actelion deal
Jan. 24, 2017
Endo reaches deal with FTC over pay-for-delay allegations
Jan. 23, 2017
7 companies to know in the emerging biosimilars field
Jan. 23, 2017
Actelion misses goal in study, but takeover talks likely unaffected
Jan. 23, 2017
Biosimilars: What's in a name?
Jan. 23, 2017
Bristol-Myers nixes hopes of early filing for Opdivo combo
Jan. 20, 2017
Earnings preview: 7 biopharmas to watch
Jan. 19, 2017
FDA details thinking on off-label communications
Jan. 19, 2017
Chinese API supplier lands in hot water with FDA
Jan. 18, 2017
Cellceutix fires back against short-seller accusations
Jan. 18, 2017
FDA spells out expectations on biosimilar interchangeability
Jan. 18, 2017
Why Jay Bradner thinks Novartis can recharge drug discovery
Jan. 17, 2017
Supreme Court to review key biosimilar dispute
Jan. 17, 2017
FDA issues long-awaited guidance on biosimilar naming
Jan. 12, 2017
Kite confident as CAR-T readout nears
Jan. 12, 2017
NCI launches new cancer drug formulary to speed combo trials
Jan. 11, 2017
JPM: Day 2 round-up
Jan. 11, 2017
JPM: Valeant sells off Dendreon, skincare brands for $2.1B
Jan. 10, 2017
JPM: Vertex stakes out cautious 2017 forecasts
Jan. 9, 2017
JPM: Ipsen snatches up Merrimack's Onivyde for $575M
Jan. 8, 2017
Judge hands Amgen major patent victory over PCSK9 rivals
Jan. 6, 2017
FDA to drugmakers: Don't let manufacturing lead to rejection
Jan. 5, 2017
Alexion faults tone at top, management pressure in Soliris investigation
Jan. 5, 2017
Amgen notches another win in patent dispute with Sanofi, Regeneron
Jan. 4, 2017
Tiny Rana makes a play for mRNA with Shire deal
Jan. 4, 2017
Gates Foundation invests $50M in Intarcia for anti-HIV work
Jan. 3, 2017
Threat grows for biologics makers as biosimilars take root
Dec. 29, 2016
As R&D returns take a hit, some pharmas are ramping up spending
Dec. 24, 2016
Teva pays up $520M to settle bribery charges
Dec. 22, 2016
Vitality secures approvals for cannabinoid facility
Dec. 22, 2016
A rough year for biotech IPOs
Dec. 22, 2016
FDA warns drugmakers on misleading marketing
Dec. 21, 2016
Incyte puts up $200M in bispecifics deal with Merus
Dec. 21, 2016
Allergan picks up regenerative med company for $2.9B
Dec. 20, 2016
Conatus soars on Novartis deal
Dec. 20, 2016
Editas locks down rights to add-on CRISPR tech
Dec. 19, 2016
Nasdaq shuffles biotech index ranks, highlighting 2016 hits, misses
Dec. 19, 2016
Ophthotech shrinks staff in wake of Fovista setback
Dec. 16, 2016
CRISPR biotechs band together in IP pact
Dec. 16, 2016
20 states sue 6 generic drugmakers over price fixing
Dec. 15, 2016
Biogen cuts jobs in MA manufacturing slimdown
Dec. 15, 2016
First charges come in generic price-fixing probe
Dec. 14, 2016
Sanofi, Celgene flagged for misleading DTC ads
Dec. 14, 2016
Bristol-Myers plans R&D overhaul, site shutdowns
Dec. 13, 2016
Cempra makes CEO change ahead of FDA decision
Dec. 13, 2016
Armed with IPO cash, CRISPR biotechs grow gene-editing tech
Dec. 12, 2016
Alexion CEO, CFO out amid Soliris investigation
Dec. 12, 2016
Purdue lands rights to psoriasis drug in diversification deal
Dec. 12, 2016
Biogen boosted by early Alzheimer's data
Dec. 9, 2016
Former pharma execs arrested in bribery scheme
Dec. 8, 2016
Sun Pharma faces new worries at key Halol plant
Dec. 8, 2016
'Cures' clears Senate in 94-5 vote
Dec. 8, 2016
Pfizer hit with record fine in UK for drug price hike
Dec. 7, 2016
AbbVie breast cancer drug falls short in Phase 2
Dec. 7, 2016
Sage locks in regulatory path for postpartum depression drug
Dec. 6, 2016
Kite begins march to market
Dec. 6, 2016
Juno turns to JCAR017 amid Rocket setback
Dec. 5, 2016
Alnylam scores ASH win in hemophilia
Dec. 5, 2016
Novartis forges ahead with lead CAR-T
Dec. 5, 2016
Eli Lilly, Boehringer secure CV label for Jardiance
Dec. 2, 2016
House passes 'Cures' in overwhelming vote
Dec. 1, 2016
Alnylam touts hemophilia drug's edge over Roche rival
Nov. 30, 2016
Arrowhead nixes clinical pipeline, trims staff
Nov. 30, 2016
ASH preview: CAR-Ts, mixed results and pipeline progress
Nov. 30, 2016
Recro Pharma notches second Phase 3 win for pain drug
Nov. 28, 2016
Juno halts CAR-T trial after new patient deaths
Nov. 23, 2016
AstraZeneca restarts halted durvalumab trials
Nov. 22, 2016
Halozyme falls after AbbVie nixes partnered program
Nov. 21, 2016
Ex-Valeant exec arrested in Philidor kickback scheme
Nov. 17, 2016
Ex-FDA official settles insider trading charges
Nov. 16, 2016
Boxed warning added to label of Bayer's Essure
Nov. 16, 2016
Data in hand, The Medicines Co. speeds PCSK9 plans
Nov. 15, 2016
Costs for many Medicare drugs continue steady rise
Nov. 15, 2016
Dynavax drops on FDA rejection of hep B vaccine
Nov. 14, 2016
CHMP decision round-up; PTC wins reprieve
Nov. 11, 2016
Valeant hit with another FDA warning letter
Nov. 10, 2016
As rival surges forward, Juno touts CAR-T pipeline
Nov. 10, 2016
FDA invites pharma input in off-label debate
Nov. 9, 2016
The Medicines Co. abandons heart drug, focus all on PCSK9si
Nov. 8, 2016
Biogen eyes quick launch for SMA drug
Nov. 7, 2016
5 trends turning biotech toward incubators
Nov. 7, 2016
Advice to an emerging biotech
Nov. 7, 2016
Key people to know in early drug development
Nov. 7, 2016
Portola broadens AndexXa partnership with Daiichi
Nov. 3, 2016
Doctors willing to prescribe biosimilars, survey shows
Nov. 2, 2016
What would a Salix sale do for Valeant?
Nov. 2, 2016
Shire confident in hemophilia despite looming pricing challenge
Nov. 1, 2016
Amid pricing scrutiny, Amgen CEO predicts more value-based contracts
Oct. 31, 2016
Third Rock Ventures secures $616M in new biotech fund
Oct. 31, 2016
Czech drugmaker hit with FDA warning letter
Oct. 27, 2016
Continuing M&A spree, Allergan picks up Motus for $200M
Oct. 27, 2016
The Medicines Co. moves cholesterol drug forward as sales fall
Oct. 26, 2016
Humana to cover Sarepta's DMD drug with caveats
Oct. 26, 2016
Lilly says complete Sola failure unlikely
Oct. 25, 2016
Merck cements advantage in I/O with first-line approval
Oct. 24, 2016
Aduro hit with partial hold, sending shares spiraling
Oct. 24, 2016
Alkermes surges on antidepressant success
Oct. 21, 2016
Dimension beefs up AAV manufacturing
Oct. 20, 2016
Single placebo response derails Rigel study
Oct. 20, 2016
Merck lays groundwork for biosimilar push
Oct. 19, 2016
CAR-T ready for flight, says Kite
Oct. 19, 2016
Earnings guide: A preview of 9 big pharmas in Q3
Oct. 18, 2016
Medicines Co. scores positive results for PCSK9 drug
Oct. 18, 2016
FDA snubs PTC appeal for Duchenne drug
Oct. 17, 2016
Bluebird touts upgrades to gene therapy
Oct. 16, 2016
Insulin makers become casualties of pricing war
Oct. 13, 2016
AstraZeneca halts asthma study in blow to Synairgen
Oct. 12, 2016
Merck inks pay-for-performance deal to boost diabetes drugs
Oct. 11, 2016
Takeda broadens oncology pipeline with Crescendo deal
Oct. 10, 2016
Downfall of a unicorn: How Theranos fell apart
Oct. 10, 2016
Major US insurer snubs Sarepta's Duchenne drug
Oct. 9, 2016
Theranos shuts down labs, lays off 340
Oct. 6, 2016
Novartis shakes up R&D, closing down two biologics units
Oct. 5, 2016
Sarepta steps up DMD dealmaking
Oct. 4, 2016
Biosimilars emerge in US, but what to call them?
Oct. 3, 2016
AstraZeneca furthers sell-off strategy with new deal
Oct. 3, 2016
Regeneron slips on trial setback for Eylea combo
Sept. 30, 2016
FDA cites Chinese manufacturers for GMP lapses
Sept. 29, 2016
Novartis, Amgen score Phase 3 win for migraine drug
Sept. 29, 2016
Will staff cuts help Novo stay competitive?
Sept. 29, 2016
Boehringer gets option to buy in I/O deal
Sept. 28, 2016
Kite bolsters lead with positive CAR-T data
Sept. 27, 2016
Pfizer nixes split plans, opts to remain one company
Sept. 26, 2016
Indivior stumbles as US states file antitrust suit
Sept. 23, 2016
FDA approval in hand, Sarepta plans for future studies
Sept. 22, 2016
Moderna lifts curtain on manufacturing plant plans
Sept. 22, 2016
Gilead shutters study for anti-MMP9 drug
Sept. 22, 2016
Allergan pays steep premium for Tobira and NASH drugs
Sept. 20, 2016
Drama at FDA: 5 things to know about the Sarepta approval
Sept. 19, 2016
Sarepta skyrockets as FDA approves DMD drug
Sept. 19, 2016
Valeant: rebates on heart drugs are coming
Sept. 19, 2016
Novavax short on options after vaccine fails trial
Sept. 16, 2016
Eisai ramps up precision med efforts with new unit
Sept. 15, 2016
Lonza builds out gene therapy offerings
Sept. 15, 2016
Novo pulls 71,000 kits of glucagon med from US market
Sept. 15, 2016
AcelRx stock jumps after trial success
Sept. 15, 2016
UN group urges 'de-linkage' of R&D costs from drug prices
Sept. 14, 2016
BIO blames insurers in pushback on drug pricing
Sept. 14, 2016
Roche bolsters evidence for MS drug Ocrevus
Sept. 14, 2016
Irish startup secures $17M Series A
Sept. 13, 2016
Generic drugmaker under federal pricing probe
Sept. 12, 2016
Aveo halts study of lung cancer drug
Sept. 12, 2016
Horizon adds rare disease drugs in $800M Raptor deal
Sept. 12, 2016
CRISPR closes in on $90M IPO
Sept. 12, 2016
J&J pushes forward with hep C triple-combo
Sept. 9, 2016
Allergan highlights new drug potential
Sept. 9, 2016
Fresh off new funding, Moderna plans new manufacturing plant
Sept. 8, 2016
FDA renews ban on Indian drugmaker after fresh violations
Sept. 8, 2016
Bluebird proceeds with late-stage trial after key improvement
Sept. 8, 2016
Gilead comments on split rumors
Sept. 8, 2016
Tonix shelves fibromyalgia plans after Phase 3 miss
Sept. 7, 2016
Karyopharm tees up filing for multiple myeloma drug
Sept. 7, 2016
Jazz subsidiary warned over misbranding of cancer drug
Sept. 6, 2016
Allergan CEO disavows 'predatory pricing'
Sept. 6, 2016
Flush from Pfizer deal, Medivation execs set to cash in
Sept. 6, 2016
Momenta pulls the plug on pancreatic cancer drug
Sept. 2, 2016
Sunovion snaps up Cynapsus in $624M deal
Sept. 1, 2016
In wake of generics deal, Teva to close New York plant
Sept. 1, 2016
Theranos stumbles in efforts to sell Zika test: report
Sept. 1, 2016
Gilead hit with patent suit over hepatitis C drugs
Sept. 1, 2016
Roche's Tecentriq ready to compete in lung cancer
Sept. 1, 2016
Weighing in on EpiPen, PhRMA calls for reforms at FDA
Aug. 31, 2016
Novartis breaks up CAR-T unit in major shift
Aug. 31, 2016
Novartis wins US approval for biosimilar Enbrel
Aug. 30, 2016
Looking past FDA snub, Portola touts new Andexxa data
Aug. 30, 2016
Trial failure dashes Vectura's hopes for wider use of asthma drug
Aug. 30, 2016
Stada elects new chairman after activist pressure
Aug. 30, 2016
Moderna reels in $450M in new funding
Aug. 29, 2016
Biosim threat stiffens for Roche's Herceptin
Aug. 28, 2016
Mallinckrodt sharpens specialty pharma focus
Aug. 26, 2016
Theranos planning appeal of federal penalties
Aug. 26, 2016
Sagent recalls injectable antibiotic
Aug. 25, 2016
Denali secures $130M in new funding, reveals R&D plans
Aug. 25, 2016
FDA unexpectedly snubs Amgen drug
Aug. 25, 2016
Pfizer continues dealmaking with antibiotics buy
Aug. 24, 2016
With PDUFA date for rucaparib set, Clovis eyes rebound
Aug. 24, 2016
MI Labs to biotechs: Call us home
Aug. 16, 2016
OncoGenex scrambles after trial fail
Aug. 16, 2016
Aurinia succeeds, but safety concerns loom
Aug. 16, 2016
Veteran CEO of German drugmaker Stada resigns
Aug. 15, 2016
Chinese regulators advance overhaul of drug manufacturing
Aug. 15, 2016
AcelRx meets goal in Phase 3, but stock slips
Aug. 15, 2016
Gilead can recoup legal fees from Merck, judge says
Aug. 15, 2016
Drug pricing studies anger industry, ICER pushes back
Aug. 12, 2016
Valeant tumbles on report of fraud investigation
Aug. 11, 2016
NIH shuts down facility used to produce drugs for clinical trials
Aug. 10, 2016
Pfizer temporarily shutters Indian facility after inspections
Aug. 9, 2016
Seizing CAR-T lead, Kite readies commercial-scale manufacturing
Aug. 9, 2016
Editas continues to expand CRISPR capabilities with new deal
Aug. 9, 2016
Kite steps up plans for leading CAR-T, putting pressure on Juno
Aug. 8, 2016
Novo Nordisk sees pricing challenges 'intensifying'
Aug. 8, 2016
Despite trial restart, Juno pushes back launch timeline for CAR-T therapy
Aug. 5, 2016
Bristol-Myers' Opdivo fails key lung cancer study, stocks ricochet
Aug. 5, 2016
Pfizer cuts 151 jobs at New York plant
Aug. 4, 2016
Chinese drug manufacturer lies to FDA, promptly gets banned
Aug. 4, 2016
Gilead: 'We stand behind the pricing of our therapies'
Aug. 4, 2016
Takeover rumors juice Biogen stock, but fade fast
Aug. 3, 2016
Amgen secures rights to cancer immunotherapy from biotech Advaxis
Aug. 2, 2016
Theranos founder Holmes touts new tech despite unanswered questions
Aug. 2, 2016
Biogen snaps up rights to neuromuscular disease drug after trial success
Aug. 1, 2016
GSK, Verily launch $715 million bet on bioelectronic medicines
Aug. 1, 2016
Higher Humira sales lift AbbVie in Q2
July 29, 2016
Merck's Keytruda continues gains, driving Q2 revenues higher
July 29, 2016
Bristol-Myers revenues climb on strong Opdivo performance
July 28, 2016
Amgen boosts sales forecast as Q2 profits jump
July 27, 2016
US regulators clear Teva, Allergan generics deal
July 27, 2016
TauRx Alzheimer's drug flunks late-stage study
July 27, 2016
Lilly CEO John Lechleiter to retire by year-end
July 27, 2016
Health plans slow to adopt new drug value assessments: survey
July 26, 2016
Lilly blames stiff competition for lower US sales of lung cancer drugs
July 26, 2016
Gilead trims guidance as Hepatitis C drug sales slip
July 25, 2016
Alzheon readies Phase 3 study of Alzheimer's drug
July 25, 2016
AbbVie partners with Bristol-Myers in combo study of cancer drugs
July 25, 2016
Fresh off Relistor win, Valeant hits FDA roadblock for eye drug
July 22, 2016
Chinese team to test CRISPR in humans, jumping ahead of planned US study
July 22, 2016
Swiss group Galencia buys US biotech Relypsa for $1.5 billion
July 21, 2016
Biogen CEO George Scangos to step down
July 21, 2016
Roche sales buoyed by cancer drugs
July 21, 2016
Federal court thwarts AstraZeneca efforts to block Crestor copies
July 20, 2016
Valeant wins backing of FDA panel for psoriasis drug
July 20, 2016
Bristol-Myers settles for $30 million over California kickback claims
July 19, 2016
Ziopharm says patient death unrelated to gene therapy
July 19, 2016
Novartis doubles down on new drugs as sales slump for top cancer med
July 19, 2016
FDA: Flood of orphan drug applications slowing review process
July 19, 2016
Roche blood cancer drug falls short in late-stage study
July 18, 2016
With new additions, PhRMA opens door to generics drugmaker Teva
July 15, 2016
FDA staff raises safety concerns for Valeant psoriasis drug
July 15, 2016
Why Allergan thinks an 'open science' approach can help it develop new antibiotics
July 14, 2016
Amgen partners with Daiichi to market biosimilars in Japan
July 14, 2016
Large Valeant investor sold off remaining stake last quarter
July 13, 2016
Juno restarts suspended CAR-T trial after FDA lifts clinical hold
July 12, 2016
Merck trims research jobs at three sites, shifts drug discovery focus
July 12, 2016
Sage soars after small study of postpartum depression drug shows benefit
July 12, 2016
Cancer drug could benefit Parkinson's patients, study shows
July 11, 2016
Facing major penalties, Theranos could be forced to change business
July 11, 2016
FDA staff backs Amgen biosim of AbbVie's Humira
July 8, 2016
Theranos founder banned from blood-testing business
July 8, 2016
Juno CAR-T trial halted by FDA after three patient deaths
July 7, 2016
AbbVie bet on Ablynx gets boost after arthritis drug shows promise
July 7, 2016
Pfizer pledges to disclose risks of opioid addiction
July 6, 2016
Federal appeals court reaffirms biosimilar launch rules
July 5, 2016
Medivation enters takeover talks with Sanofi after rejecting new bid
July 5, 2016
UK cost agency knocks back Bristol-Myers' Opdivo in kidney cancer
July 5, 2016
Bristol-Myers buys Cormorant Pharma, eyes cancer combo potential
July 5, 2016
AstraZeneca sells off dermatology drug rights to LEO Pharma
July 1, 2016
Major trade group slams 'misleading' analysis of drug prices
June 30, 2016
Tesaro soars after ovarian cancer drug meets Phase 3 goal
June 29, 2016
In narrow vote, FDA panel supports heart benefit claim for Lilly diabetes drug
June 29, 2016
VA teams up with IBM's supercomputer Watson to expand precision medicine
June 28, 2016
Harvard Pilgrim inks pay-for-performance deals with Novartis, Eli Lilly
June 28, 2016
Gilead wins FDA nod for pan-genotypic Hep C drug
June 28, 2016
Pfizer to open first Asia biotech center in China
June 28, 2016
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
June 28, 2016
FDA halts testing of Regulus' Hep C drug, sending shares into tailspin
June 27, 2016
GW Pharma shares jump on Phase 3 data for cannabis-based drug
June 27, 2016
Sanofi, Boehringer trade business units in $25 billion swap
June 27, 2016
Teva seals deal to market copy of AstraZeneca diabetes drug
June 24, 2016
Brexit vote creates new uncertainty for UK, EU pharma industry
June 24, 2016
Epizyme partners with Roche to test cancer drug combo
June 23, 2016
Pfizer plans to close Colorado production facility
June 23, 2016
AstraZeneca writes off $80 million after US authorities say nasal flu vaccine ineffective
June 23, 2016
First human study of CRISPR approved by federal panel
June 22, 2016
Startup biotech Homology Med aims to 'leapfrog' CRISPR competitors
June 21, 2016
Teva, Allergan continue to shed assets with $586 million sale to Impax
June 21, 2016
Takeda begins field testing norovirus vaccine
June 21, 2016
NIH turns down request to override cancer drug patent
June 20, 2016
Doubling down on biosimilars, Novartis plans five launches by 2020
June 20, 2016
NIH panel to review proposal for first in human test of CRISPR
June 17, 2016
Pfizer begins construction on $200 million biologics plant in MA
June 16, 2016
Merck's Keytruda beats out chemotherapy in lung cancer study
June 16, 2016
Facing legal troubles and declining sales, Aegerion to merge with Canadian QLT
June 15, 2016
Marathon Pharma latest company to try for approval of Duchenne drug
June 15, 2016
Shire buys rights to Pfizer bowel disease drug
June 14, 2016
FDA warns of kidney risks for diabetes drugs from Janssen, AstraZeneca
June 14, 2016
Former Dendreon CEO leads Alpine Immune to $48 million financing
June 14, 2016
Report: Oncology drove record pharma dealmaking in 2015
June 9, 2016
Small biotech Accera reinvents itself, takes aim at Alzheimer's treatment
June 8, 2016
FDA asks Sarepta for more data on muscular dystrophy drug
June 7, 2016
AbbVie lung cancer drug shows promise, but has high expectations to meet
June 5, 2016
With eye to growing Chinese market, Novartis opens major R&D hub in Shanghai
June 2, 2016
Global cancer drug spending rises, set to surpass $150 billion by 2020
June 2, 2016
FDA warns another Indian API supplier on manufacturing lapses
June 1, 2016
Activist investor Icahn acquires large stake in Allergan
June 1, 2016
Despite stock plunge, former Valeant CEO to collect $9 million in severance pay
June 1, 2016
BioMarin ends Duchenne program, withdraws EU application for drisapersen
May 31, 2016
Intercept shares climb on FDA approval of liver drug
May 31, 2016
Jazz Pharma snaps up leukemia drug with $1.5 billion deal for Celator
May 31, 2016
EMA knocks back multiple myeloma drug from Takeda
May 27, 2016
Roche's Gazyva notches early trial success
May 27, 2016
FDA rejects AstraZeneca hyperkalemia drug, boosting competitor Relypsa
May 27, 2016
Bristol-Myers attacks cost-effectiveness study of cancer drug
May 26, 2016
Sanofi diabetes drug wins adcomm support, keeping pace with Novo
May 26, 2016
Theranos hit with class-action lawsuit over blood-testing claims
May 25, 2016
Sarepta shares jump after FDA delays decision on Duchenne drug
May 25, 2016
Despite recent R&D setbacks, Lilly aims to launch 20 new drugs by 2023
May 24, 2016
Janssen's multiple myeloma drug passes muster in Europe
May 24, 2016
After setback, GSK's Breo gets boost from real-world data
May 24, 2016
Eyeing US market, Samsung applies for approval of biosimilar Remicade
May 24, 2016
EMA removes warning from Pfizer smoking cessation drug
May 23, 2016
Ahead of key panel vote, FDA staff raises concerns over Novo diabetes drug
May 23, 2016
Immunotherapies from Merck and Bristol-Myers help extend life, new data shows
May 19, 2016
Theranos corrects two years of test results: WSJ
May 19, 2016
Roche to shutter Clarecastle plant after it can't find buyer
May 19, 2016
Roche's much-anticipated immontherapy wins early approval for bladder cancer
May 19, 2016
New patent threat looms for AbbVie's blockbuster Humira
May 18, 2016
Bristol-Myers extends lead with new Opdivo indication
May 17, 2016
Novartis splits drugs unit, pharma chief to depart
May 17, 2016
AstraZeneca asthma drug clears phase 3 studies, boosting respiratory pipeline
May 17, 2016
Biogen unveils gene therapy collaboration with UPenn experts
May 16, 2016
After criticism, Valeant details plans for hospital discounts on heart drugs
May 16, 2016
With generics deal pending, Teva's Europe portfolio attracts buyers
May 16, 2016
Pfizer adds eczema drug in $5.2 billion deal for Anacor
May 16, 2016
Aegerion to plead guilty to misbranding cholesterol drug, will pay $40 million
May 12, 2016
After shutting down cancer drug, Clovis now facing government investigations
May 12, 2016
Baxter reportedly top suitor for Indian injectables maker
May 12, 2016
Amid losses, Endo plans cutbacks at Par manufacturing facilities
May 12, 2016
U.K. cost agency rejects Bristol-Myer's Opdivo for lung cancer
May 12, 2016
Theranos president to leave company as federal scrutiny continues
May 12, 2016
Colombian diplomat warns of fallout from Novartis patent battle
May 11, 2016
Drugmakers hit with federal investigations of PBM contracts
May 11, 2016
India awards patent to Gilead's Sovaldi
May 10, 2016
Allergan plans $10 billion stock buyback as it waits for Teva cash
May 10, 2016
FDA flags potential safety risk for Lilly antipsychotic drug
May 10, 2016
'The sharks are circling:' 5 insights from the Valeant documents
May 10, 2016
Medicines Co. sells off cardiovascular drugs to Italy's Chiesi
May 9, 2016
Lower sales of generic drugs weigh on Teva's first-quarter revenue
May 9, 2016
As new CEO takes over, Valeant forms committee to oversee drug pricing
May 6, 2016
As Big Pharma circles, Medivation makes case for independence
May 6, 2016
FDA reaches agreement with Xellia on troubled manufacturing plant
May 5, 2016
Biogen spinoff set to build out hemophilia pipeline
May 5, 2016
Sanofi threatens Medivation board with hostile bid
May 5, 2016
Merck sales hit by generic competition in US, Europe
May 5, 2016
Report: Pfizer considering takeover offer for sought-after Medivation
May 4, 2016
Israeli pharma company provides rare disease drug for free after it can't find patients
May 3, 2016
Pfizer revenues surge as vaccines, new drugs rack up sales
May 3, 2016
Boosting focus on neurology, Biogen to spin off hemophilia business
May 3, 2016
Eagle Pharma hits FDA with lawsuit after cancer drug denied orphan exclusivity
May 2, 2016
Gene editing biotech Homology Med launches with $44 million in financing
May 2, 2016
Federal judge reopens high-stakes patent case between Merck and Gilead
May 1, 2016
As profits drop, AstraZeneca trims costs and sharpens focus on R&D
April 29, 2016
With CEO Pearson set to bow out, Valeant files much-delayed annual report
April 29, 2016
As new drugs take hold, Lilly ramps up R&D spend
April 28, 2016
Adding to changes at top, Valeant reportedly set to turn over board
April 28, 2016
Sanofi pressures Medivation to take $9.3 billion bid
April 28, 2016
Valeant officials apologize to Senate panel for steep price hikes
April 27, 2016
Valeant increased prices too aggressively, CEO expected to tell Senate panel
April 27, 2016
FDA demands additional studies for Catalyst's firdapse
April 26, 2016
Seven New York insurers end restrictions on coverage for hepatitis C drugs
April 26, 2016
New drug sales boost Lilly revenue, yet profits tumble
April 26, 2016
Despite efforts of advocates, FDA panel votes against Sarepta's Duchenne drug
April 25, 2016
Valeant names ex-Perrigo chief Joseph Papa as CEO
April 25, 2016
Inside the development of Venclexta, AbbVie's new leukemia drug
April 22, 2016
Adding to cosmetic portfolio, Allergan buys Topokine for $85 million
April 22, 2016
AstraZeneca launches massive drug discovery effort, aims to sequence 2 million genomes
April 22, 2016
Continuing scrutiny, FDA hits Sri Krishna with warning over 'serious' data violations
April 21, 2016
China investigates 3 drugmakers for manufacturing violations, orders recall
April 21, 2016
Novartis income falls as key cancer drug battles generic competition
April 21, 2016
Bluebird Bio gene therapy sees encouraging early results in treatment of rare brain disease
April 21, 2016
NIH suspends work at two facilities, including T-cell research
April 19, 2016
Bristol-Myers' Opdivo shows promise in head, neck cancers
April 19, 2016
Roche beats Q1 expectations on strong oncology sales
April 19, 2016
With new studies, Boehringer and Lilly to pit diabetes drug against heart failure
April 19, 2016
Theranos reportedly facing new federal investigations
April 19, 2016
Bristol-Myers' Opdivo gets boost from long-term survival data
April 18, 2016
Review of NCI facilities halts patient enrollment in Kite T-cell studies
April 17, 2016
Report: AstraZeneca considering bid for cancer biotech Medivation
April 17, 2016
Further downgrade to Valeant ratings reportedly could trigger forced selling
April 15, 2016
Swiss company Lonza Group seeking to acquire CRO Catalent: report
April 14, 2016
FDA advocates for adoption of speedier drug manufacturing technique
April 14, 2016
Report: U.S. drug spending hit $310 billion last year
April 14, 2016
Regulator proposes 2-year ban of Theranos founder Elizabeth Holmes
April 13, 2016
Biosimilars gain momentum — and pharma leaders are noticing
April 13, 2016
Large bondholder hits Valeant with default notice
April 12, 2016
Clovis' lung cancer drug fails to impress FDA panel
April 12, 2016
Japanese genomic analysis characterizes liver cancer into six types
April 12, 2016
CRISPR biotech Intellia strikes licensing deal with Regeneron, readies IPO
April 11, 2016
Life after Shkreli: KaloBios promises affordable drugs, no 'price gouging'
April 11, 2016
AbbVie and Roche team wins FDA approval for leukemia drug
April 11, 2016
Roche's anti-PDL1 immunotherapy granted fast track status
April 11, 2016
Valeant board asks CEO Pearson to cooperate with Senate panel subpoena
April 10, 2016
Amid questions on accuracy of blood tests, Theranos bulks up its medical board
April 8, 2016
After Alzheimer's drug passes safety review, AstraZeneca and Lilly push into Phase 3
April 8, 2016
Inspections by FDA hurting Indian drug exports, says Dr. Reddy's chairman
April 7, 2016
Why partnerships are crucial for pushing vaccine R&D forward
April 7, 2016
Allergan snaps up rights to Alzheimer's drugs in deal with Heptares
April 7, 2016
Lenders give Valeant a reprieve, agree to extend deadline for filing annual report
April 7, 2016
After merger with Pfizer implodes, Allergan's acquisition options open up
April 6, 2016
Pfizer calls off $160 billion merger with Allergan
April 6, 2016
Remicade copy clears FDA, becomes second biosim to win approval in U.S.
April 5, 2016
In phase 3 collaboration, Merck and Pfizer testing PDL1/TKI combo
April 5, 2016
Valeant panel concludes Philidor investigation, finds no more misstatements
April 5, 2016
New US inversion rules could wreck Pfizer-Allergan deal
April 5, 2016
Report: Valeant cuts sales force for female libido drug
April 4, 2016
Gilead's new HIV formulation continues success with FDA approval of Descovy
April 4, 2016
Study shows no clinical benefit from Lilly's failed cholesterol drug
April 4, 2016
GSK gene therapy for rare immune disorder wins EMA approval
April 3, 2016
Samsung Bioepis' biosim of Remicade clears regulatory hurdle in EU
April 1, 2016
FTC alleges Endo struck illegal deals to delay release of generic drugs
April 1, 2016
Canadian securities regulator issues cease trade orders to Valeant management
April 1, 2016
As aging blockbusters come off patent, new opportunities emerge for biosim manufacturers
March 31, 2016
In quest to expand diabetes market share, Novo breaks ground on $1.8b U.S. plant
March 31, 2016
GSK won't file drug patents in low-income countries
March 31, 2016
Indian drug regulator to begin surprise inspections at manufacturing sites
March 30, 2016
FTC asks Pfizer, Allergan for more details on proposed mega-merger
March 30, 2016
With deadline looming, Valeant asks lenders for more time to file report
March 30, 2016
Cambridge-based Aveo settles fraud charges with SEC for $4 million
March 30, 2016
FDA panel says benefits outweigh risks for Acadia's Parkinson's drug
March 29, 2016
Sun Pharma expands presence in Japan with $293 million deal for Novartis drugs
March 29, 2016
Sanders, other lawmakers urge NIH to consider patent override on cancer drug
March 28, 2016
New phase 2 data boosts prospects for Alder's migraine drug
March 28, 2016
Spending on Vertex's Kalydeco consumed 86% of Scottish rare disease fund's budget
March 28, 2016
Sprout investors reportedly allege Valeant overpriced Addyi
March 27, 2016
Gilead to pay Merck $200 million in damages for Hep C patents
March 25, 2016
Patent case in India highlights tensions between public health, protecting innovation
March 24, 2016
Head of Valeant's largest investor retires as drugmaker's troubles hit fund
March 24, 2016
A month after FDA spurned DMD drug, PTC laying off 18% of workforce
March 23, 2016
In major stroke study, AstraZeneca's Brilinta fails to beat aspirin
March 23, 2016
Merck wins major victory in hep C patent case against Gilead
March 22, 2016
Eli Lilly's ixekizumab gets green light from FDA
March 22, 2016
As stock crashed, Valeant's largest shareholder reportedly sold 1.5m shares
March 22, 2016
In response to crisis, FDA mandates new warnings for opioid painkillers
March 22, 2016
Citing 'improper conduct,' Valeant attempts to oust former CFO from board
March 21, 2016
Valeant's Pearson will step down as CEO; Ackman joins Board
March 21, 2016
U.K. cost regulator confirms final approval for Novartis' Entresto
March 20, 2016
Johnson & Johnson's psoriasis drug Stelara succeeds in Phase 3
March 18, 2016
In new deal, Kite Pharma partnering with Roche on cancer immunotherapy
March 18, 2016
McKesson laying off 1,600 employees
March 17, 2016
Scientists develop new type of stem cell with only half a genome
March 17, 2016
Amgen signs 'flexible manufacturing agreement' with CMO Patheon
March 17, 2016
GSK head Andrew Witty to step down in spring 2017
March 17, 2016
Jury rules in favor of Amgen in PCSK9 patent fight
March 16, 2016
After forecast cut, Valeant stock collapses as investors head for the exits
March 16, 2016
As EMA investigates, Gilead halts six clinical trials of cancer drug
March 15, 2016
Express Scripts: Growth in overall U.S. drug spending slowed in 2015
March 15, 2016
Teva's $40.5 billion generics deal with Allergan hits FTC snag
March 15, 2016
Roche signs potential $1 billion cancer immunotherapy deal with Cambridge biotech
March 15, 2016
Valeant cuts 2016 revenue projections by $1.5 billion
March 15, 2016
Amid investor criticism, AstraZeneca considers link between executive pay and revenue goal
March 14, 2016
Doctors Without Borders moves to block Pfizer patent in India
March 11, 2016
Sanofi's sarilumab bests blockbuster Humira in Phase 3 study
March 11, 2016
EC approves Teva's $40.5B deal for Allergan generics arm
March 10, 2016
House Oversight committee presses Valeant on details of withheld documents
March 10, 2016
First generic version of Viagra in the U.S. approved by FDA
March 10, 2016
Death from French drug trial likely due to high doses of compound
March 10, 2016
Senate bill adding Zika to priority review program highlights R&D incentives
March 10, 2016
VA broadens Hep C coverage to all veterans, not just the sickest
March 10, 2016
FDA accepts new Keytruda data, opening door for wider indication
March 9, 2016
Report: Theranos continued blood tests even as quality checks revealed flaws
March 9, 2016
Hoping for rebound, Valeant adds three new members to board
March 9, 2016
US prescription drug spending increases to an estimated $457 billion in 2015
March 9, 2016
CMS proposes overhaul to Part B drug reimbursement
March 8, 2016
India will reportedly refrain from issuing compulsory drug licenses
March 8, 2016
Ending 20-year partnership, Sanofi and Merck close down joint vaccines venture
March 8, 2016
Bayer, Novartis, Sanofi lose big on Venezuelan bonds
March 7, 2016
EMA debuts new program to speed up review of innovative drugs
March 7, 2016
In high-profile failure, Celldex's cancer vaccine crashes in phase 3
March 7, 2016
AbbVie paying Boehringer $595M upfront to gain access to psoriasis drug
March 7, 2016
Janssen, AbbVie's Imbruvica approved by FDA for first line treatment of CLL
March 4, 2016
Moody's downgrades pharma industry outlook, cites lower pricing
March 4, 2016
UK Autolus reels in £40 million for CAR-T development
March 4, 2016
Much-anticipated trial shows Novo's Victoza reduces CV risk
March 4, 2016
Kite, Juno ramping up commercial manufacturing capacity for CAR-T
March 3, 2016